Notices. Notice

24,333 words·~111 min read·/register/2007/05/23/07-2549

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Statement of Organization, Functions and Delegation of Authority Notice is hereby given that I have redelegated to the Director, Program Operations Division, Office of Head Start, the following authorities vested in me by the Assistant Secretary of Administration for Children and Families in the memoranda dated February 16, 2007.

(a)Authorities Delegated 1. Approve and disapprove refunding and supplemental funding applications for existing grantees, not including designated interim grantees. 2. Approve and disapprove collaboration grant applications authorized under 42 U.S.C. 9835. 3. Approve and disapprove contract proposals for award, not including proposals for national interim grantee contracts. 4. Approve and disapprove quality improvement plans

(QIP)as required under 42 U.S.C. 9836A(d)(2)(B). 5. Conduct, as the responsible HHS official, informal meetings with current grantees or current or prospective delegate agencies as authorized by 45 CFR part 1303.11 and 1303.12. 6. Conduct, as the responsible HHS official, informal meetings authorized by 45 CFR part 1303.21 related to appeals by current or prospective delegate agencies. 7. Serve as the Approving Official to sign audit determination letters only where resolution does not involve a cost disallowance. 8. Approve and issue termination and suspension actions resulting from monitoring review reports approved and issued by the Regional Office.

(b)Limitations 1. The approval of grant applications requires concurrence of the appropriate Grants Officer. 2. The approval of contract proposals and awards are subject to the requirements of the Federal Acquisition Regulations and require consultation with the Director, Office of Head Start and the concurrence of the Contracting Officer. 3. The approval and issuance of terminations and suspensions resulting from monitoring review reports approved and issued by the Regional Office require the concurrence of the Director, Office of Head Start. 4. This redelegation shall be exercised under financial and administrative requirements applicable to all Administration for Children and Families authorities. 5. Any redelegation shall be in writing and prompt notification must be provided to all affected managers, supervisors, and other personnel, and requires the concurrence of the Deputy Assistant Secretary for Administration.

(c)Effective Date This redelegation was effective on April 26, 2007.

(d)Effect on Existing Delegations This redelegation of authority supersedes all previous delegations from the Director, Office of Head Start, on these subjects. I hereby affirm and ratify any actions taken by the Director, Program Operations Division which, in effect, involved the exercise of these authorities prior to the effective date of this redelegation. Dated: May 15, 2007. Channell Wilkins, Director, Office of Head Start. [FR Doc. E7-9925 Filed 5-22-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Statement of Organization, Functions and Delegation of Authority Notice is hereby given that I have redelegated to the Regional Program Managers, American Indian Alaska Native Program Branch Chief, and Migrant and Seasonal Program Branch Chief, Office of Head Start, the following authorities vested in me by the Director, Office of Head Start, in the memoranda dated April 26, 2007.

(QIP)as required under 42 U.S.C. 9836A(d)(2)(B). 5. Conduct, as the responsible HHS official, informal meetings with current grantees or current or prospective delegate agencies as authorized by 45 CFR 1303.11 and 1303.12. 6. Conduct, as the responsible HHS official, informal meetings authorized by 45 CFR part 1303.21 related to appeals by current or prospective delegate agencies. 7. Serve as the Approving Official to sign audit determination letters only where resolution does not involve a cost disallowance. 8. Approve and issue termination and suspension actions resulting from monitoring review reports approved and issued by the Regional Office.

(c)Effective Date This redelegation was effective on April 26, 2007.

(d)Effect on Existing Delegations This redelegation of authority supersedes all previous delegations from the Director, Office of Head Start, on these subjects. I hereby affirm and ratify any actions taken by any Regional Program Manager, the American Indian Alaska Native Program Branch Chief or the Migrant and Seasonal Program Branch Chief which, in effect, involved the exercise of these authorities prior to the effective date of this redelegation. Dated: May 14, 2007. Renee Perthuis, Director, Program Operations Division. [FR Doc. E7-9928 Filed 5-22-07; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006E-0260] Determination of Regulatory Review Period for Purposes of Patent Extension; ORENCIA AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined the regulatory review period for ORENCIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product. ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of the biological product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human biological product and continues until FDA grants permission to market the biological product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human biological product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B). FDA recently approved for marketing the human biological product ORENCIA (abatacept). ORENCIA is indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying anti-rheumatic drugs, such as methotrexate or TNF antagonists. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for ORENCIA (U.S. Patent No. 5,851,795) from Bristol-Myers Squibb Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated September 5, 2006, FDA advised the Patent and Trademark Office that this human biological product had undergone a regulatory review period and that the approval of ORENCIA represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period. FDA has determined that the applicable regulatory review period for ORENCIA is 3,803 days. Of this time, 3,536 days occurred during the testing phase of the regulatory review period, while 267 days occurred during the approval phase. These periods of time were derived from the following dates: 1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective* : July 28, 1995. FDA has verified the applicant's claim that the date the investigational new drug application became effective was on July 28, 1995. 2. *The date the application was initially submitted with respect to the human biological product under section 351 of the Public Health Service Act (42 U.S.C. 262)* : April 1, 2005. The applicant claims March 31, 2005, as the date the biologics license application

(BLA)for ORENCIA (BLA 125118) was submitted. However, FDA records indicate that BLA 125118 was received on April 1, 2005. 3. *The date the application was approved* : December 23, 2005. FDA has verified the applicant's claim that BLA 125118 was approved on December 23, 2005. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,414 days of patent term extension. Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments and ask for a redetermination by July 23, 2007. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 19, 2007. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30. Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: May 2, 2007 Jane A. Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research. [FR Doc. E7-9945 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006E-0501] Determination of Regulatory Review Period for Purposes of Patent Extension; GARDASIL AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined the regulatory review period for GARDASIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product. ADDRESSES: Submit written or electronic comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of the biological product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human biological product and continues until FDA grants permission to market the biological product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human biological product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B). FDA recently approved for marketing the human biological product GARDASIL (Quadrivalent Human Papillomavirus Recombinant Vaccine). GARDASIL is indicated for vaccination in females 9 to 26 years of age for prevention of the following diseases caused by Human Papillomavirus

(HPV)Types 6, 11, 16, and 18: Cervical cancer, genital warts (condyloma acuminata), and the following precancerous or dysplastic lesions: Cervical adenocarcinoma in situ (AIS); cervical intraepithelial neoplasia

(CIN)grade 1, grade 2, and grade 3; vulvar intraepithelial neoplasia

(VIN)grade 2 and grade 3; and vaginal intraepithelial neoplasia

(VaIN)grade 2 and grade 3. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for GARDASIL (U.S. Patent No. 5,820,870) from Merck & Co., Inc., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated February 6, 2007, FDA advised the Patent and Trademark Office that this human biological product had undergone a regulatory review period and that the approval of GARDASIL represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period. FDA has determined that the applicable regulatory review period for GARDASIL is 2,215 days. Of this time, 2,031 days occurred during the testing phase of the regulatory review period, while 184 days occurred during the approval phase. These periods of time were derived from the following dates: 1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective* : May 17, 2000. The applicant claims May 14, 2000, as the date the investigational new drug application

(IND)became effective. However, FDA records indicate that the IND effective date was May 17, 2000, which was 30 days after FDA receipt of the IND. 2. *The date the application was initially submitted with respect to the human biological product under section 351 of the Public Health Service Act (42 U.S.C. 262)* : December 7, 2005. FDA has verified the applicant's claim that the product license application

(BLA)for GARDASIL (BLA 125126/0) was initially submitted on December 7, 2005. 3. *The date the application was approved* : June 8, 2006. FDA has verified the applicant's claim that BLA 125126/0 was approved on June 8, 2006. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,200 days of patent term extension. Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments and ask for a redetermination by July 23, 2007. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 19, 2007. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30. Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: May 7, 2007. Jane A. Axelrad Associate Director for Policy, Center for Drug Evaluation and Research. [FR Doc. E7-9950 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2007E-0002] Determination of Regulatory Review Period for Purposes of Patent Extension; ELAPRASE AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined the regulatory review period for ELAPRASE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product. ADDRESSES: Submit written or electronic comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human biological products, the testing phase begins when the exemption to permit the clinical investigations of the human biological product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human biological product and continues until FDA grants permission to market the biological product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human biological product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B). FDA recently approved for marketing the human biological product ELAPRASE (idursulfase). ELAPRASE is indicated for patients with Hunter Syndrome (Mucopolysaccharidosis II). Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for ELAPRASE (U.S. Patent No. 5,932,211) from Women's and Children's Hospital, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated February 6, 2007, FDA advised the Patent and Trademark Office that this human biological product had undergone a regulatory review period and that the approval of ELAPRASE represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period. FDA has determined that the applicable regulatory review period for ELAPRASE is 2,008 days. Of this time, 1,764 days occurred during the testing phase of the regulatory review period, while 244 days occurred during the approval phase. These periods of time were derived from the following dates: 1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective* : January 25, 2001. The applicant claims March 12, 2001, as the date the investigational new drug application

(IND)became effective. However, FDA records indicate that the IND effective date was January 25, 2001, which was 30 days after FDA receipt of the IND. 2. *The date the application was initially submitted with respect to the human biological product under section 351 of the Public Health Service Act (42 U.S.C. 262)* : November 23, 2005. FDA has verified the applicant's claim that the biologics license application

(BLA)for ELAPRASE (BLA 125151) was initially submitted on November 23, 2005. 3. *The date the application was approved* : July 24, 2006. FDA has verified the applicant's claim that BLA 125151 was approved on July 24, 2006. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,103 days of patent term extension. Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments and ask for a redetermination by July 23, 2007. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 19, 2007. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30. Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: May 7, 2007. Jane A. Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research. [FR Doc. E7-9951 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2002P-0399] Determination That ESTROSTEP 21 (Ethinyl Estradiol and Norethindrone Acetate) Tablets Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined that ESTROSTEP 21 (ethinyl estradiol and norethindrone acetate) tablets were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for the combination drug ethinyl estradiol and norethindrone acetate tablets, 0.02 milligram (mg)/1 mg, 0.03 mg/1 mg, and 0.035 mg/1 mg. FOR FURTHER INFORMATION CONTACT: Mary Catchings, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041. SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is typically a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug. The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, drugs are removed from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (§ 314.162)(21 CFR 314.162)). Under § 314.161(a)(1)(21 CFR 314.161(a)(1)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness before an ANDA that refers to that listed drug may be approved. FDA may not approve an ANDA that does not refer to a listed drug. ESTROSTEP 21 (ethinyl estradiol and norethindrone acetate) tablets, 0.02 mg/1 mg, 0.03 mg/1 mg, and 0.035 mg/1 mg, are the subject of approved NDA 20-130 held by Warner Chilcott. ESTROSTEP 21 tablets, 0.02 mg/1 mg, 0.03 mg/1 mg, and 0.035 mg/1 mg, were approved on October 9, 1996, as oral contraceptives indicated for the prevention of pregnancy in women who elect to use these products as a method of contraception. FDA also approved ESTROSTEP FE under NDA 20-130 on October 9, 1996, for the same indication. On July 1, 2001, FDA approved ESTROSTEP 21 and ESTROSTEP FE for the treatment of moderate acne vulgaris under NDA 21-276. Both ESTROSTEP 21 and ESTROSTEP FE provide a gradually increasing estrogen dose with a constant dose of progestin. Both drugs provide the same dosage regimen of oral contraceptive tablets for the first 21 days of a 28-day cycle. ESTROSTEP FE provides an additional seven ferrous fumarate tablets. The ferrous fumarate tablets, which are nonhormonal and serve no therapeutic purpose, are added to facilitate patient compliance by the use of a 28-day regimen where the patient takes a pill every day. Except for the nontherapeutic ferrous fumarate tablets, ESTROSTEP 21 and ESTROSTEP FE have the same therapeutic regimen. ESTROSTEP 21 is listed in the Orange Book as a discontinued product. ESTROSTEP FE, currently named ESTROSTEP, remains on the list of currently marketed drug products. Barr Laboratories, Inc., submitted a citizen petition dated September 4, 2002 (Docket No. 2002P-0399/CP1), under 21 CFR 10.30 and § 314.161, requesting that FDA determine whether ESTROSTEP 21 tablets had been discontinued from sale for reasons of safety or effectiveness. In a letter dated December 1, 2004, Warner Chilcott confirmed to the agency that the firm never commercially marketed ESTROSTEP 21 in the United States. In previous instances (see the **Federal Register** of December 30, 2002 (67 FR 79640 at 79641) (addressing a relisting request for Diazepam Autoinjector)), FDA has concluded that, for purposes of §§ 314.161 and 314.162, never marketing an approved drug product is equivalent to withdrawing the drug from sale. The agency has determined that ESTROSTEP 21 tablets, 0.02 mg/1 mg, 0.03 mg/1 mg, and 0.035 mg/1 mg, were not withdrawn from sale for reasons of safety or effectiveness. In support of this finding, we note that Warner Chilcott continues to market ESTROSTEP FE, which contains the same therapeutic dosage regimen as ESTROSTEP 21. The petitioner identified no data or other information suggesting that ESTROSTEP 21 was withdrawn from sale as a result of safety or effectiveness concerns. FDA has independently evaluated relevant literature and data for possible postmarketing adverse event reports associated with this combination drug product and has found no information that would indicate this product was withdrawn from sale for reasons of safety or effectiveness. After considering the citizen petition and reviewing agency records, FDA determines that for the reasons outlined in this document, ESTROSTEP 21 tablets, 0.02 mg/1 mg, 0.03 mg/1 mg, and 0.035 mg/1 mg, were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list ESTROSTEP 21 in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to ESTROSTEP 21 may be approved by the agency as long as they meet all relevant legal and regulatory requirements for approval of ANDAs. If FDA determines that labeling for these drugs products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling. Dated: May 15, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7-9949 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2007N-0191] Determination That Protamine Sulfate Injection and 26 Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined that the 27 drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness.This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) for the drug products, and it will allow FDA to continue to approve ANDAs for the products. FOR FURTHER INFORMATION CONTACT: Mary Catchings, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20855, 301-594-2041. SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug. The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, drugs are withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness:

(1)Before an ANDA that refers to that listed drug may be approved or

(2)whenever a listed drug is voluntarily withdrawn from sale, and ANDAs that refer to the listed drug have been approved. Section 314.161(d) provides that if FDA determines that a listed drug was removed from sale for safety or effectiveness reasons, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug. FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicants, FDA withdrew approval of NDA 6-460 for Protamine Sulfate Injection, NDA 18-675 for TAVIST Syrup, NDA 19-243 for PROVENTIL Inhalation Solution, NDA 19-471 for CARDIZEM SR Capsules, and NDA 19-817 for PERSANTINE Injection in the **Federal Register** of March 4, 2005 (70 FR 10651), NDA 8-857 for PHENERGAN Injection in the **Federal Register** of May 5, 2004 (69 FR 25124), and NDA 13-400 for ALDOMET Tablets and NDA 13-401 for ALDOMET Injection in the **Federal Register** of June 16, 2006 (71 FR 34940)). Application No. Drug Applicant NDA 6-460 Protamine Sulfate Injection, 10 milligrams (mg)/milliliter

(mL)in a 25-mL vial Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285 NDA 6-773 ARTANE (trihexyphenidyl hydrochloride (HCl)) Tablets, 2 mg and 5 mg Lederle, c/o Wyeth Pharmaceuticals, P.O. Box 8299, Philadelphia, PA 19101-8299 NDA 8-857 PHENERGAN (promethazine HCl) Injection, 25 mg/mL and 50 mg/mL in 1-mL vials Wyeth Pharmaceuticals, P.O. Box 8299, Philadelphia, PA 19101-8299 NDA 9-149 THORAZINE (chlorpromazine HCl) Tablets, 10, 25, 50, 100, and 200 mg GlaxoSmithKline, 2301 Renaissance Blvd., King of Prussia, PA 19406 NDA 11-145 DIURIL (chlorothiazide) Tablets, 250 mg and 500 mg Merck & Co., Inc., Sumneytown Pike, BLA-20, P.O. Box 4, West Point, PA 19486 NDA 11-664 DECADRON (dexamethasone) Tablets, 0.25, 4, and 6 mg Do. NDA 11-808 MELLARIL (thioridazine HCl) Tablets, 10, 15, 25, 50, 100, 150, and 200 mg Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936 NDA 11-870 DIURIL (chlorothiazide) Suspension, 250 mg/5 mL Merck & Co., Inc. NDA 13-400 ALDOMET (methyldopa) Tablets, 125, 250, and 500 mg Do. NDA 13-401 ALDOMET (methyldopate HCl) Injection, 50 mg/mL Do. NDA 16-363 LASIX (furosemide) Injection, 10 mg/mL Aventis Pharmaceuticals, Inc., 200 Crossing Blvd., Bridgewater, NJ 08807-0890 NDA 17-391 IMURAN (azathioprine) Injection, 100 mg base/vial Prometheus Laboratories, 5739 Pacific Center Blvd., San Diego, CA 92121-4203 NDA 17-939 TAGAMET (cimetidine HCl) Injection, 300 mg/2 mL GlaxoSmithKline NDA 18-513 CHENIX (chenodiol) Tablets, 250 mg Axcan Scandipharm, Inc., 22 Inverness Center Parkway, Birmingham, AL 35242-4814 NDA 18-675 TAVIST (clemastine fumarate) Oral Syrup, 0.5 mg/5 mL Novartis Consumer Health, Inc., 200 Kimball Dr., Parsippany, NJ 07054-0622 NDA 18-922 LODINE (etodolac) Capsules, 200 mg; LODINE Tablets, 400 mg and 500 mg Wyeth Pharmaceuticals, Inc. NDA 19-201 VOLTAREN (diclofenac sodium) Delayed-Release Tablets, 25 mg and 50 mg Novartis Pharmaceuticals, Inc. NDA 19-243 PROVENTIL (albuterol sulfate) Inhalation Solution, 0.5% and 0.083% Schering-Plough Corporation, 2000 Galloping Hill Rd., Kenilworth, NJ 07033 NDA 19-434 TAGAMET HCl (cimetidine HCl) in Sodium Chloride 0.9% in Plastic Container, EQ 6 mg/mL GlaxoSmithKline NDA 19-471 CARDIZEM SR (diltiazem HCl) Capsules, 60, 90, 120, and 180 mg Biovail Laboratories, Inc., c/o Bioavail Technologies Ltd., 700 Route 202/206 North, Bridgewater, NJ 08807-0980 NDA 19-817 PERSANTINE (dipyridamole) Injection, 5 mg/mL Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, CT 06877-0368 NDA 20-144 TRANSDERM-NITRO (nitroglycerin), 0.1 mg/hour (hr), 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr, 0.8 mg/hr Novartis Pharmaceuticals Corp. NDA 20-584 LODINE (etodolac) XL Tablets, 600 mg Wyeth Pharmaceuticals, Inc. NDA 21-110 RAPAMUNE (sirolimus) Tablets, 5 mg Wyeth Pharmaceuticals, Inc. NDA 50-477 NEBCIN (tobramycin sulfate) Injection, 10 mg/mL Eli Lilly and Co. NDA 50-519 NEBCIN (tobramycin sulfate) Injection, 1.2 grams/vial Do. ANDA 62-008 NEBCIN (tobramycin sulfate) Injection, 40 mg/mL Do. FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. Approved ANDAs that refer to the NDAs and ANDA listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs and ANDA. Additional ANDAs for the products may also be approved by the agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling. Dated: May 15, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7-9962 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2004E-0319] Determination of Regulatory Review Period for Purposes of Patent Extension; BEXTRA AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)has determined the regulatory review period for BEXTRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments* . FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive. A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the human drug product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted, as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B). FDA recently approved for marketing the human drug product BEXTRA (valdecoxib). BEXTRA is indicated for relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for BEXTRA (U.S. Patent No. 5,633,272) from G.D. Searle, LLC, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated August 31, 2004, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of BEXTRA represented the first permitted commercial marketing or use of the product. Thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period. FDA has determined that the applicable regulatory review period for BEXTRA is 1,767 days. Of this time, 1,462 days occurred during the testing phase of the regulatory review period, while 305 days occurred during the approval phase. These periods of time were derived from the following dates: 1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective* : January 16, 1997. The applicant claims January 15, 1997, as the date the investigational new drug application

(IND)became effective. However, FDA records indicate that the IND effective date was January 16, 1997, which was 30 days after FDA receipt of the IND. 2. *The date the application was initially submitted with respect to the human drug product under section 505(b) of the act* : January 16, 2001. FDA has verified the applicant's claim that the new drug application

(NDA)for Bextra (NDA 21-341) was initially submitted on January 16, 2001. 3. *The date the application was approved* : November 16, 2001. FDA has verified the applicant's claim that NDA 21-341 was approved on November 16, 2001. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 276 days of patent term extension. Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES ) written or electronic comments and ask for a redetermination by July 23, 2007. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 19, 2007. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30. Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: May 2, 2007. Jane A. Axelrad, Associate Director for Policy, Center for Drug Evaluation and Research. [FR Doc. E7-9957 Filed 5-22-07; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on

(240)276-1243. Project: Pretesting of Substance Abuse Prevention and Treatment and Mental Health Services Communication Messages—(OMB No. 0930-0196)—Extension As the Federal agency responsible for developing and disseminating authoritative knowledge about substance abuse prevention, addiction treatment, and mental health services and for mobilizing consumer support and increasing public understanding to overcome the stigma attached to addiction and mental illness, the Substance Abuse and Mental Health Services Administration (SAMHSA) is responsible for development and dissemination of a wide range of education and information materials for both the general public and the professional communities. This submission is for generic approval and will provide for formative and qualitative evaluation activities to

(1)assess audience knowledge, attitudes, behavior and other characteristics for the planning and development of messages, communication strategies and public information programs; and

(2)test these messages, strategies and program components in developmental form to assess audience comprehension, reactions and perceptions. Information obtained from testing can then be used to improve materials and strategies while revisions are still affordable and possible. The annual burden associated with these activities is summarized below. Activity No. of respondents Responses respondent Hours per response Total hours Individual In-depth Interviews: General Public 400 1 .75 300 Service Providers 200 1 .75 150 Focus Group Interviews: General Public 3,000 1 1.5 4,500 Service Providers 1,500 1 1.5 2,250 Telephone Interviews: General Public 335 1 .08 27 Service Providers 165 1 .08 13 Self-Administered Questionnaires: General Public 2,680 1 .25 670 Service Providers 1,320 1 .25 330 Gatekeeper Reviews: General Public 1,200 1 .50 600 Service Providers 900 1 .50 450 Total 11,700 9,290 Written comments and recommendations concerning the proposed information collection should be sent by June 22, 2007 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202-395-6974. Dated: May 7, 2007. Elaine Parry, Acting Director, Office of Program Services. [FR Doc. E7-9900 Filed 5-22-07; 8:45 am] BILLING CODE 4162-20-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5117-N-44] Notice of Submission of Proposed Information Collection to OMB; Early Doctoral Student Research Grant Program AGENCY: Office of the Chief Information Officer, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. Doctoral students will receive grants to complete their dissertations related to HUD subjects. DATES: *Comments Due Date:* June 22, 2007. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2528-0216) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail *Lillian_L._Deitzer@HUD.gov* or telephone

(202)708-2374. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Deitzer or from HUD's Web site at *http://www5.hud.gov:63001/po/i/icbts/collectionsearch.cfm* . SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. This notice also lists the following information: *Title of Proposal:* Early Doctoral Student Research Grant Program. *OMB Approval Number:* 2528-0216. *Form Numbers:* SF-424, SF-424 Supplement, HUD-424CB, SFLLL, HUD-27300, HUD-2880, HUD-2944A, HUD-96010, HUD-96011. *Description of the Need for the Information and Its Proposed Use:* Doctoral students will receive grants to complete their dissertations related to HUD subjects. *Frequency of Submission:* On occasion, Semi-annually, Other Final Report. Number of respondents Annual responses x Hours per response = Burden hours Reporting Burden 80 1.56 21.68 2710 *Total Estimated Burden Hours:* 2,710. *Status:* Extension of a current collection. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended. Dated: May 18, 2007. Lillian L. Deitzer, Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer. [FR Doc. E7-9953 Filed 5-22-07; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5117-N-43] Notice of Submission of Proposed Information Collection to OMB; Mortgage Insurance Termination; Application for Premium Refund or Distributive Share Payment AGENCY: Office of the Chief Information Officer, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. The Mortgage Insurance Termination Information is used by FHA-approved lenders to terminate FHA insurance to comply with HUD requirements. The Application for Premium Refund or Distributive Share Payment is used by homeowners to apply for the unearned portion of the mortgage insurance premium or a distributive share payment. DATES: *Comments Due Date:* June 22, 2007. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2502-0414) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail *Lillian_L._Deitzer@HUD.gov* or telephone

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. This notice also lists the following information: *Title of Proposal:* Mortgage Insurance Termination; Application for Premium Refund or Distributive Share Payment. *OMB Approval Number:* 2502-0414. *Form Numbers:* HUD-27050-A and HUD-27050-B. *Description of the Need for the Information and Its Proposed Use:* The Mortgage Insurance Termination Information is used by FHA-approved lenders to terminate FHA insurance to comply with HUD requirements. The Application for Premium Refund or Distributive Share Payment is used by homeowners to apply for the unearned portion of the mortgage insurance premium or a distributive share payment. *Frequency of Submission:* On occasion. Number of respondents Annual responses x Hours per response = Burden hours Reporting Burden 462,349 2.17 0.157 157,932 *Total Estimated Burden Hours:* 157,932. *Status:* Extension of a currently approved collection. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended. Dated: May 18, 2007. Lillian L. Deitzer, Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer. [FR Doc. E7-9955 Filed 5-22-07; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5117-N-42] Notice of Submission of Proposed Information Collection to OMB; Multifamily Mortgagee's Application for Insurance Benefits AGENCY: Office of the Chief Information Officer, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. Mortgagees provide information to apply for insurance benefits. HUD uses the information provided to cancel multifamily mortgage insurance contracts and payments of mortgage insurance. DATES: *Comments Due Date:* June 22, 2007. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2502-0419) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail *Lillian_L._Deitzer@HUD.gov* or telephone

(202)708-2374. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Deitzer or from HUD's Web site at *http://www5.hud.gov:63001/po/i/icbts/collectionsearch.cfm.* SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. This notice also lists the following information: *Title of Proposal:* Multifamily Mortgagee's Application for Insurance Benefits. *OMB Approval Number:* 2502-0419. *Form Numbers:* HUD-2747. *Description of the Need for the Information and its Proposed Use:* Mortgagees provide information to apply for insurance benefits. HUD uses the information provided to cancel multifamily mortgage insurance contracts and payments of mortgage insurance. *Frequency of Submission:* On occasion. Number of respondents Annual responses x Hours per response = Burden hours Reporting Burden 110 1 0.08 9 *Total Estimated Burden Hours:* 9. *Status:* Extension of current collection. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended. Dated: May 18, 2007. Lillian L. Deitzer, Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer. [FR Doc. E7-9958 Filed 5-22-07; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5117-N-41] Notice of Submission of Proposed Information Collection to OMB; Disclosure of Adjustable Rate Mortgages

(ARMs)Rates AGENCY: Office of the Chief Information Officer, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. Lenders must provide mortgagors with adjustable rate mortgages an annual ARM Disclosure Notice at least 25 days before any adjustment to a mortgagor's monthly payment may occur, and the mortgagee must inform the borrower of the changed interest rate, monthly mortgage amount, the current index interest rate value, and how the payment adjustment was calculated. HUD reviews lenders loan files to ensure lenders are in compliance. DATES: *Comments Due Date:* June 22, 2007. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2502-0322) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail *Lillian_L._Deitzer@HUD.gov* or telephone

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(ARMs)Rates. *OMB Approval Number:* 2502-0322. *Form Numbers:* None. *Description of the Need for the Information and Its Proposed Use:* Lenders must provide mortgagors with adjustable rate mortgages an annual ARM Disclosure Notice at least 25 days before any adjustment to a mortgagor's monthly payment may occur, and the mortgagee must inform the borrower of the changed interest rate, monthly mortgage amount, the current index interest rate value, and how the payment adjustment was calculated. HUD reviews lenders loan files to ensure lenders are in compliance. *Frequency of Submission:* Annually. Number of respondents Annual responses x Hours per response = Burden hours Reporting Burden 20,000 11 0.05 11,000 *Total Estimated Burden Hours:* 11,000. *Status:* Extension of a currently approved collection. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended. Dated: May 18, 2007. Lillian L. Deitzer, Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer. [FR Doc. E7-9959 Filed 5-22-07; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR-5117-N-40] Notice of Submission of Proposed Information Collection to OMB; Certificate of Need for Health Facilitiy and Assurance of Enforcement of State Standards AGENCY: Office of the Chief Information Officer, HUD. ACTION: Notice. SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget

(OMB)for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. FHA appraisers, mortgagors, and nonprofit entities use form HUD-2576-HF to evaluate the property as security for a long-term insured mortgage. The Certificate of Need is used to obtain approval from HUD for insured loans for nursing homes and intermediate care facilities. DATES: *Comments Due Date:* June 22, 2007. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval Number (2502-0210) and should be sent to: HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; fax: 202-395-6974. FOR FURTHER INFORMATION CONTACT: Lillian Deitzer, Departmental Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail *Lillian_L._Deitzer@HUD.gov* or telephone

(202)708-2374. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Ms. Deitzer or from HUD's Web site at *http://www5.hud.gov:63001/po/i/icbts/collectionsearch.cfm.* SUPPLEMENTARY INFORMATION: This notice informs the public that the Department of Housing and Urban Development has submitted to OMB a request for approval of the information collection described below. This notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:

(1)Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2)Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information;

(3)Enhance the quality, utility, and clarity of the information to be collected; and

(4)Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. This notice also lists the following information: *Title of Proposal:* Certificate of Need for Health Facilitiy and Assurance of Enforcement of State Standards. *OMB Approval Number:* 2502-0210. *Form Numbers:* HUD-2576-HF. *Description of the Need for the Information and Its Proposed Use:* FHA appraisers, mortgagors, and nonprofit entities use form HUD-2576-HF to evaluate the property as security for a long-term insured mortgage. The Certificate of Need is used to obtain approval from HUD for insured loans for nursing homes and intermediate care facilities. *Frequency of Submission:* On occasion. Number of respondents Annual responses x Hours per response = Burden hours Reporting Burden 50 1 0.5 25 *Total Estimated Burden Hours:* 25. *Status:* Extension of a currently approved collection. Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended. Dated: May 18, 2007. Lillian L. Deitzer, Departmental Paperwork Reduction Act Officer, Office of the Chief Information Officer. [FR Doc. E7-9960 Filed 5-22-07; 8:45 am] BILLING CODE 4210-67-P DEPARTMENT OF THE INTERIOR Bureau of Land Management [ID-330-1430-ELL; DSG070001; IDI-35511] Notice of Realty Action; Modified Competitive Sale of Public Land, Custer County, ID AGENCY: Bureau of Land Management, Interior. ACTION: Notice of realty action. SUMMARY: The Bureau of Land Management

(BLM)has examined and determined that one parcel of public land approximately 103.88 acres, located in Custer County, Idaho is suitable for disposal by modified competitive sale to all qualified members of the public, pursuant to Sections 203 and 209 of the Federal Land Policy and Management Act (FLPMA) of 1976, as amended. DATES: Interested parties may submit comments to the BLM Challis Field Office Manager, at the below address. Comments must be received no later than July 9, 2007. Only written comments will be accepted. ADDRESSES: Detailed information including but not limited to documentation relating to compliance with all applicable environmental and cultural resource laws is available for review at the BLM Challis Field Office. Address all written comments concerning this Notice to David Rosenkrance, BLM Challis Field Office Manager, 801 Blue Mountain Rd, Challis, Idaho 83226-9304. Before including your address, phone number, e-mail address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. SUPPLEMENTARY INFORMATION: The BLM has identified the Lezamiz Family Limited Partnership

(FLP)(John T. Lezamiz, General Partner/Representative) as the proponent in this modified competitive sale. As the proponent, Mr. Lezamiz is reserved the right to match the highest bid. The purchase price will be determined through an open bidding process. The minimum opening bid will be no less than the appraised fair market value as determined by a Department of the Interior appraisal. The following described public land in Custer County, Idaho has been determined to be suitable for sale at a price to be determined in an open bidding process under Sections 203 and 209 of the Federal Land Policy and Management Act of 1976, as amended (43 U.S.C. 1713 and 1719). The BLM has determined this land is difficult to economically manage [as part of the public lands] and that resource values will not be affected by the disposal of this parcel of public land. The parcel is identified for disposal in the Challis Resource Management Plan (1999), and its disposal would be in the public interest. In accordance with 43 CFR 2711.3-2(a)(2), this parcel is being offered by modified competitive sale to the Lezamiz FLP and all qualified members of the public. John T. Lezamiz/Lezamiz FLP has been named the proponent based on two circumstances. The first is the fact that John T. Lezamiz is the adjacent landowner immediately to the south of the subject parcel. Second, Mr. Lezamiz is the current grazing permit holder, and has historically used the parcel in that capacity. Additionally, the Lezamiz FLP arranged for and paid for the environmental impact analysis and resource clearances completed for this proposed action. The parcel is fenced, bordered to the west and south by private property, and has no improvements. If selected as the highest bidder, failure or refusal of Lezamiz FLP to submit payment within 180 days of the sale of the parcel will constitute a waiver of this preference consideration. This parcel may then be offered for sale on a competitive basis. If another member of the public is selected as the highest bidder and fails to submit payment within 180 days of the sale, the parcel may again be offered on a competitive basis. The parcel is described as follows: Boise Meridian, Idaho T. 7 N., R. 25 E., section 30, lots 13, 14 and 15. The area described contains 103.88 acres, more or less. The market value, not less than the current fair market value, utilizing modified competitive bid sale procedures, is yet to be determined by Department of the Interior appraisal. The patent, when issued, will contain a reservation to the United States for ditches and canals under the authority of the United States pursuant to the Act of August 30, 1890, 26 Stat. 391 (43 U.S.C. 945). No warranty of any kind, express or implied, is given by the United States as to title, whether or to what extent the land may be developed, its physical condition, future uses, or any other circumstance or condition. The conveyance of the parcel will not be on a contingency basis. However, to the extent required by law, the parcel is subject to the requirements of section 120(h) of the Comprehensive Environmental Response, Compensation and Liability Act, (42 U.S.C. 9620(h)) (CERCLA), as amended by the Superfund Amendments and Reauthorization Act

(SARA)of 1988, (100 Stat. 1670). Notice is hereby given that the above-described lands have been examined and no evidence was found to indicate any hazardous substances had been stored for one year or more, nor had any hazardous substances been disposed of or released on the subject property. A mineral potential report will be completed by the BLM prior to the execution of the sale. If the report concludes the subject parcel contains minerals of value they shall be reserved to the United States. If the report determines the subject parcel contains no known mineral values, mineral interests will be conveyed simultaneously with the surface. A separate non-refundable filing fee of $50.00 is required from the purchaser for the conveyance of the mineral interest. Upon publication of this notice in the **Federal Register** , the land described above will be segregated from appropriation under the public land laws, including the general mining laws. The segregation will end upon issuance of patent or other documents of conveyance for such lands, upon publication in the **Federal Register** of a termination of the segregation, or May 26, 2009, whichever occurs first, unless extended by the BLM State Director in accordance with 43 CFR 2611.2(a), prior to the termination date. Comments must be received by the BLM Challis Field Manager, Idaho Falls District Office, at the address stated above, on or before the date noted in the DATES section above. Any adverse comments will be reviewed by the Idaho Falls District Manager, who may sustain, vacate or modify this realty action. In the absence of any objections, or adverse comments, this proposed realty action will become the final determination of the Department of the Interior. The land will not be offered for sale until at least 60 days after the date of publication of this notice in the **Federal Register** . The BLM may accept or reject any or all offers, or withdraw any land or interest in the land from sale, if, in the opinion of the authorized officer, consummation of the sale would not be fully consistent with FLPMA, or other applicable laws. FOR FURTHER INFORMATION CONTACT: Tim Vanek, Realty Specialist, at the above address or call:

(208)879-6218. Authority: 43 CFR 2711.1-2(c). Joe Kraayenbrink, District Manager, Idaho Falls District. [FR Doc. E7-9939 Filed 5-22-07; 8:45 am] BILLING CODE 4310-GG-P DEPARTMENT OF THE INTERIOR Bureau of Land Management [ES-966-1420-BJ-TRST] Group No. 177, Wisconsin Eastern States: Filing of Plat of Survey AGENCY: Bureau of Land Management, Interior. ACTION: Notice of filing of plat of survey; Wisconsin. SUMMARY: The Bureau of Land Management

(BLM)will file the plat of survey of the lands described below in the BLM-Eastern States, Springfield, Virginia, 30 calendar days from the date of publication in the **Federal Register** . FOR FURTHER INFORMATION CONTACT: Bureau of Land Management, 7450 Boston Boulevard, Springfield, Virginia 22153. Attn: Cadastral Survey. SUPPLEMENTARY INFORMATION: This survey was requested by the Bureau of Indian Affairs. The lands we surveyed are: Township 46 North, Range 3 West, of the Fourth Principal Meridian, Wisconsin The plat of survey represents the dependent resurvey of a portion of the west boundary, a portion of the subdivisional lines, and the north and south center line of section 18; and the survey of the subdivision of section 18 and was approved May 11, 2007. We will place a copy of the plat we described in the open files. It will be available to the public as a matter of information. If BLM receives a protest against this survey, as shown on the plat, prior to the date of the official filing, we will stay the filing pending our consideration of the protest. We will not officially file the plat until the day after we have accepted or dismissed all protests and they have become final, including decisions on appeals. Dated: May 14, 2007. Joseph W. Beaudin, Chief Cadastral Surveyor (acting). [FR Doc. E7-9938 Filed 5-22-07; 8:45 am] BILLING CODE 4310-GJ-P DEPARTMENT OF THE INTERIOR Bureau of Land Management [CO-923-1430-ET; COC-70988] Notice of Proposed Withdrawal and Opportunity for Public Meeting; Colorado AGENCY: Bureau of Land Management, Interior. ACTION: Notice. SUMMARY: The Secretary of the Interior proposes to withdraw on behalf of the Bureau of Land Management

(BLM)4,138 acres of public lands for a period of 20 years to protect scenic, recreation, water quality, and wildlife habitat values in Routt County, Colorado. This notice temporarily segregates the lands for up to 2 years from settlement, sale, location, or entry under the general land laws, including the mining laws, and the mineral and geothermal leasing laws while the 20-year withdrawal application is being processed. DATES: Comments and requests for a public meeting must be received by August 21, 2007. ADDRESSES: Comments and meeting requests should be sent to the BLM Colorado State Director, 2850 Youngfield Street, Lakewood, Colorado 80215-7093. FOR FURTHER INFORMATION CONTACT: John Beck, BLM Colorado State Office, 303-239-3882 or at the above address. SUPPLEMENTARY INFORMATION: The applicant for the above withdrawal is the BLM at the address stated above. The petition/application requests the Secretary of the Interior to withdraw, for a period of 20 years, the following described public lands from settlement, sale, location, or entry under the general land laws, including the mining laws, and the mineral and geothermal leasing laws, subject to valid existing rights: Sixth Principal Meridian T. 6 N., R. 85 W., Sec. 13, SE 1/4 SE 1/4 , excepting and excluding the west 100 feet thereof and the north 100 feet thereof; Sec. 15, S 1/2 NE 1/4 , S 1/2 SW 1/4 , and SE 1/4 ; Sec. 21, That portion of the S 1/2 N 1/2 SE 1/4 NE 1/4 , S 1/2 SE 1/4 NE 1/4 , and E 1/2 SE 1/4 lying North and East of the centerline of the Cow Creek Road (County Road No. 45) excepting the traverse and right-of-way, whether an easement or in fee, for County Road No. 45; Sec. 22; Sec. 23, W 1/2 NW 1/4 , W 1/2 SE 1/4 NW 1/4 , SE 1/4 SE 1/4 NW 1/4 , SW 1/4 , S 1/2 N 1/2 SE 1/4 , and S 1/2 SE 1/4 ; Sec. 24, E 1/2 E 1/2 NW 1/4 , E 1/2 SW 1/4 , S 1/2 NW 1/4 SW 1/4 , SW 1/4 SW 1/4 , NW 1/4 SE 1/4 , S 1/2 SE 1/4 , W 1/2 NE 1/4 , and NE 1/4 NE 1/4 ; Secs. 25 and 26; Secs. 27, 34, and 35, those portions lying north and east of the centerline of the Cow Creek Road (County Road No. 45); *Excepting therefrom* a parcel of land containing 123.78 acres located in secs. 23 and 24 of T. 6 N., R. 85 W. of the 6th P.M., Routt County, Colorado, described as follows: Beginning at a point on the North side of an existing road (top of ridge) and on the North line of the said NW 1/4 NW 1/4 of sec. 23 from which the Northwest corner of said sec. 23 bears N89°13′32″W 164.58 feet; Thence East along the North line of the said NW 1/4 NW 1/4 of sec. 23 to the Northwest corner of the NE 1/4 NW 1/4 of sec. 23 and the Northwest corner of a parcel of land which is described at Reception Number 610794 (State of Colorado Patent No. 8350) of the Routt County Clerk and Recorders Records; Thence South along the West line of the said NE 1/4 NW 1/4 of sec. 23 and along the West line said Reception Number 610794; Thence East along the South line of the said NE 1/4 NW 1/4 of sec. 23 and along a South line said Reception Number 610794; Thence South along the West line of the said NE 1/4 SE 1/4 NW 1/4 of sec. 23 and along a West line said Reception Number 610794; Thence East along the South line of the said NE 1/4 SE 1/4 NW 1/4 of sec. 23 and along a South line said Reception Number 610794; Thence South along the West line of the said NE 1/4 of sec. 23 and along a West line said Reception Number 610794; Thence South along the West line of the said N 1/2 N 1/2 SE 1/4 of sec. 23 and along a West line said Reception Number 610794; Thence East along the South line of the said N 1/2 N 1/2 SE 1/4 of sec. 23 and along the South line said Reception Number 610794; Thence East along the South line of the said N 1/2 NW 1/4 SW 1/4 of sec. 24 and along the South line said Reception Number 610794; Thence North along the East line of the said N 1/2 NW 1/4 SW 1/4 of sec. 24 and along an East line said Reception Number 610794; Thence East along the South line of the said W 1/2 SE 1/4 NW 1/4 of sec. 24 and along a South line said Reception Number 610794; Thence North along the East line of the said W 1/2 SE 1/4 NW 1/4 of sec. 24 and along an East line said Reception Number 610794 to the VOR Boundary Line (State Lease No. S-40743); Thence along the VOR Boundary Line S12°50′38″ E 299.28 feet; Thence S33°42′38″ E 22.93 feet to the said the North side of an existing road (top of ridge); Thence along the North side of an existing road (top of ridge) the following 110 calls: Thence S50°53′35″ W 74.77 feet; Thence S30°01′45″ W 154.66 feet; Thence S28°31′35″ W 87.10 feet; Thence S69°35′54″ W 81.43 feet; Thence S85°40′20″ W 60.86 feet; Thence S49°17′24″ W 58.86 feet; Thence S41°56′59″ W 134.03 feet; Thence S37°38′18″ W 87.73 feet; Thence S15°35′30″ W 79.00 feet; Thence S49°46′21″ W 108.55 feet; Thence S12°48′13″ W 74.61 feet; Thence S38°47′34″ W 88.97 feet; Thence N85°43′33″ W 115.46 feet; Thence N31°26′52″ W 73.54 feet; Thence N14°56′20″ W 104.21 feet; Thence N56°36′48″ W 84.47 feet; Thence N86°58′32″ W 25.88 feet; Thence N54°51′32″ W 72.09 feet; Thence S85°51′12″ W 105.33 feet; Thence S61°17′43″ W 268.38 feet; Thence S40°58′52″ W 112.92 feet; Thence S52°06′13″ W 122.46 feet; Thence S60°18′48″ W 136.16 feet; Thence S76°44′29″ W 99.18 feet; Thence S86°42′26″ W 66.02 feet; Thence S68°09′27″ W 71.14 feet; Thence S72°42′33″ W 86.80 feet; Thence S76°38′34″ W 74.19 feet; Thence S58°25′05″ W 104.46 feet; Thence S83°56′22″ W 58.42 feet; Thence N64°17′55″ W 154.26 feet; Thence S84°05′15″ W 114.25 feet; Thence S88°58′19″ W 132.72 feet; Thence S68°36′20″ W 53.92 feet; Thence S76°57′09″ W 103.67 feet; Thence N82°43′50″ W 152.63 feet; Thence S65°04′59″ W 131.51 feet; Thence S81°58′30″ W 50.01 feet; Thence N66°22′44″ W 103.89 feet; Thence N67°36′04″ W 142.14 feet; Thence N81°15′18″ W 101.71 feet; Thence N88°03′08″ W 91.61 feet; Thence N85°51′10″ W 83.84 feet; Thence S63°07′53″ W 96.98 feet; Thence S87°19′55″ W 52.62 feet; Thence N81°02′21″ W 52.60 feet; Thence S72°58′28″ W 102.27 feet; Thence N85°45′58″ W 46.89 feet; Thence N76°50′26″ W 121.49 feet; Thence N66°37′46″ W 82.62 feet; Thence N70°03′27″ W 102.49 feet; Thence N86°09′48″ W 144.29 feet; Thence N61°19′11″ W 54.13 feet; Thence N77°29′21″ W 236.46 feet; Thence N65°54′30″ W 63.61 feet; Thence N51°07′21″ W 64.32 feet; Thence N39°08′23″ W 177.57 feet; Thence N63°13′32″ W 88.53 feet; Thence N35°43′27″ W 75.59 feet; Thence N66°17′06″ W 108.99 feet; Thence N57°14′02″ W 58.33 feet; Thence N82°43′22″ W 85.03 feet; Thence N37°25′09″ W 44.39 feet; Thence N24°09′53″ W 38.91 feet; Thence N47°56′52″ W 94.25 feet; Thence N41°56′57″ W 110.76 feet; Thence N25°13′06″ W 129.66 feet; Thence N41°27′24″ W 64.04 feet; Thence N11°22′34″ W 70.79 feet; Thence N41°16′24″ W 120.61 feet; Thence N59°17′37″ W 98.64 feet; Thence N62°59′30″ W 23.50 feet; Thence N32°41′09″ W 75.57 feet; Thence N41°54′29″ W 85.05 feet; Thence N29°45′20″ W 96.36 feet; Thence N04°54′34″ W 105.47 feet; Thence N17°02′34″ W 104.53 feet; Thence N42°24′33″ W 42.32 feet; Thence N73°51′48″ W 148.88 feet; Thence N66°36′39″ W 31.71 feet; Thence N45°56′30″ W 110.06 feet; Thence N37°30′18″ W 78.07 feet; Thence N29°31′07″ W 97.61 feet; Thence N39°24′56″ W 140.33 feet; Thence N31°39′34″ W 136.12 feet; Thence N41°49′43″ W 89.75 feet; Thence N68°54′22″ W 109.23 feet; Thence N51°31′11″ W 70.02 feet; Thence N15°08′01″ W 15.17 feet; Thence N15°27′12″ E 108.56 feet; Thence N21°37′52″ E 105.46 feet; Thence N06°44′53″ E 107.26 feet; Thence N03°03′35″ E 68.31 feet; Thence N21°05′16″ E 93.84 feet; Thence N00°26′24″ E 65.96 feet; Thence N09°16′03″ E 57.58 feet; Thence N18°37′13″ W 72.17 feet; Thence N37°53′14″ W 124.39 feet; Thence N61°43′36″ W 89.58 feet; Thence N50°42′33″ W 86.54 feet; Thence N53°38′51″ W 83.66 feet; Thence N37°16′48″ W 46.09 feet; Thence N17°28′58″ W 56.27 feet; Thence N06°24′06″ W 44.49 feet; Thence N16°53′31″ W 106.95 feet; Thence N05°02′10″ W 224.13 feet; Thence N14°40′37″ W 82.61 feet; Thence N28°19′20″ W 76.69 feet; Thence N11°15′24″ W 69.14 feet; Thence N00°55′11″ W 21.10 feet to the Point of Beginning. All bearings shown hereon are based upon the North line of the NE 1/4 of said sec. 24 as being N89°24′02″ W. The areas described aggregate 4,138.52 acres, more or less, in Routt County according to U.S. Government Survey and James B. Ackerman, R.L.S. #16394, of Emerald Mountain Surveys, Inc., Steamboat Springs, CO 80477. The BLM petition/application has been approved by the Assistant Secretary of the Interior. Therefore it constitutes a withdrawal proposal of the Secretary of the Interior (43 CFR 2310.1-3(e)). The purpose of the withdrawal would be to protect the scenic, recreation, water quality, and wildlife habitat values on the lands newly acquired in the Emerald Mountain Land Exchange and achieve the management objectives of the BLM Little Snake Field Office Resource Management Plan Amendment. The use of a right-of-way, an interagency or cooperative agreement would not adequately constrain non-discretionary uses that could irrevocably affect the resource values of the described lands. There are no suitable alternative sites, as the described lands contain the resource values that need protection. No water rights would be needed to fulfill the purpose of the requested withdrawal. The potential for mineral development on the described lands is low. Records relating to the proposed withdrawal can be examined by contacting John Beck at the above address or phone number. For a period of 90 days from the date of publication of this notice, all persons who wish to submit comments, suggestions, or objections in connection with the proposed withdrawal may present their views in writing to the BLM Colorado State Director at the address listed above. Comments, including names and street addresses of respondents, will be available for public review at the BLM Colorado State Office at the address listed during regular business hours, 7:45 a.m. to 4:15 p.m., Monday through Friday, except holidays. Individual respondents may request confidentiality. Before including your address, phone number, e-mail address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Notice is hereby given that an opportunity for a public meeting is afforded in connection with the proposed withdrawal. All interested persons who desire a public meeting for the purpose of being heard on the proposed withdrawal must submit a written request to the BLM Colorado State Director at the address listed above within 90 days from the date of publication of this notice. If the authorized officer determines a public meeting will be held, a notice of the time and place will be published in the **Federal Register** and a local newspaper at least 30 days before the scheduled date of the meeting. Licenses, permits, cooperative agreements, and other discretionary land use authorizations may be allowed with the approval of an authorized officer of the BLM during the segregative period. This withdrawal proposal will be processed in accordance with the regulations set forth in 43 CFR 2300. For a period of 2 years from the date of publication of this notice in the **Federal Register** , the lands will be segregated as specified above unless the application is denied or cancelled or the withdrawal is approved prior to that date. (Authority: 43 CFR 2310.3-1) Dated: May 16, 2007. John D. Beck, Chief, Branch of Lands and Realty. [FR Doc. E7-9933 Filed 5-22-07; 8:45 am] BILLING CODE 4310-JB-P DEPARTMENT OF THE INTERIOR Minerals Management Service Environmental Documents Prepared for Proposed Oil and Gas Operations on the Gulf of Mexico Outer Continental Shelf

(OCS)AGENCY: Minerals Management Service, Interior. ACTION: Notice of the availability of environmental documents, prepared for OCS Mineral Proposals on the Gulf of Mexico OCS. SUMMARY: Minerals Management Service (MMS), in accordance with Federal Regulations that implement the National Environmental Policy Act (NEPA), announces the availability of NEPA-related Site-Specific Environmental Assessments

(SEA)and Findings of No Significant Impact (FONSI), prepared by MMS for the following oil and gas activities proposed on the Gulf of Mexico OCS. FOR FURTHER INFORMATION CONTACT: Public Information Unit, Information Services Section at the number below. Minerals Management Service, Gulf of Mexico OCS Region, *Attention:* Public Information Office (MS 5034), 1201 Elmwood Park Boulevard, Room 114, New Orleans, Louisiana 70123-2394, or by calling 1-800-200-GULF. SUPPLEMENTARY INFORMATION: MMS prepares SEAs and FONSIs for proposals that relate to exploration for and the development/production of oil and gas resources on the Gulf of Mexico OCS. These SEAs examine the potential environmental effects of activities described in the proposals and present MMS conclusions regarding the significance of those effects. Environmental Assessments are used as a basis for determining whether or not approval of the proposals constitutes major Federal actions that significantly affect the quality of the human environment in the sense of NEPA Section 102(2)(C). A FONSI is prepared in those instances where MMS finds that approval will not result in significant effects on the quality of the human environment. The FONSI briefly presents the basis for that finding and includes a summary or copy of the SEA. This notice constitutes the public notice of availability of environmental documents required under the NEPA Regulations. This listing includes all proposals for which the Gulf of Mexico OCS Region prepared a FONSI in the period subsequent to publication of the preceding notice. Activity/Operator Location Date Newfield Exploration Company, Initial Development Operations Coordination Document & Right-of-Way Pipeline, SEA N-8758 & P-15812 High Island, Blocks A-353, A-366 & A-352, Leases OCS-G 24425, 24429 & 24424 respectively, located approximately 113 miles from the nearest Louisiana shoreline 11/9/2006 BP Exploration & Production, Inc., Geological & Geophysical Prospecting for Mineral Resources, SEA L07-02 Located in the central Gulf of Mexico south of Fourchon, Louisiana 1/16/2007 Anadarko Petroleum Corporation, Right-of-Way Pipeline Modification, SEA P-15101 DeSoto Canyon, Blocks 621, 620, 664, 663, 707, 706, 705 & 749; Mississippi Canyon, Blocks 789, 833, 832, 876 & 920; Leases OCS-G 23529, 23528, 23532, 25859, 25861 & 25860; located approximately 98 miles south of Gulf Shores, Alabama 1/23/2007 PGS Geophysical, Geological & Geophysical Prospecting for Mineral Resources for Multi-Klient Invest AS, Oslo, Norway, SEA L07-01 Located in the central Gulf of Mexico southeast of Cameron, Louisiana 1/24/2007 BP Exploration & Production, Inc., Geological & Geophysical Exploration of Mineral Resources, SEA L07-03 Located in the eastern Gulf of Mexico south of Fourchon, Louisiana 1/24/2007 SPN Resources, LLC, Structure Removal, SEA ES/SR 07-010, 07-012, 07-013 High Island, Blocks 134, 134 & 133 and Leases OCS-G 06158 & 18938 respectively, located 28 miles from the nearest Louisiana shoreline 1/31/2007 Dominion Exploration & Production, Inc., Structure Removal, SEA ES/SR 07-007 Ship Shoal, Block 225, Lease OCS-G 21657, located 54 miles from the nearest Louisiana shoreline 1/31/2007 Maritech Resources, Inc., Structure Removal, SEA ES/SR 07-011 Vermilion, Block 57, Lease OCS-G 03977, located 10 miles from the nearest Louisiana shoreline 1/31/2007 Maritech Resources, Inc., Structure Removal, SEA ES/SR 07-006 West Cameron, Block 206, OCS-G 03496, located 33 miles from the nearest Louisiana shoreline 2/1/2007 Chevron U.S.A., Inc., Structure Removal, SEA ES/SR 07-017 Viosca Knoll, Block 161, Lease OCS-G 06876, located 43 miles from the nearest Louisiana shoreline 2/6/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 07-002 Brazos, Block 436, Lease OCS-G 04258, located 12 miles from the nearest Texas shoreline 2/7/2007 Remington Oil & Gas Corporation, Structure Removal, SEA ES/SR 07-016 East Cameron, Block 140, Lease OCS-G 25950, located 40 miles from the nearest Louisiana shoreline 2/7/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 07-003 East Cameron, Block 222, Lease OCS-G 02037, located 67 miles from the nearest Louisiana shoreline 2/7/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 06-008 East Cameron, Block 231, Lease OCS-G 02038, located 69 miles from the nearest Louisiana shoreline 2/7/2007 Chevron U.S.A., Inc., Structure Removal, SEA ES/SR 06-011 South Timbalier, Block 51, Lease OCS-G 01240, located 10 miles from the nearest Louisiana shoreline 3/31/2006 Newfield Exploration Company, Structure Removal, SEA ES/SR 06-017 West Cameron, Block 146, Lease OCS-G 01996, located 21 miles from the nearest Louisiana shoreline 3/31/2006 SPN Resources, Structure Removal, SEA ES/SR 07-014 High Island, Block A-153, Lease OCS-G 18946, located 84 miles from the nearest Texas shoreline 2/8/2007 Stone Energy Corporation, Structure Removal, SEA ES/SR 07-024 South Marsh Island, Block 235, Lease OCS-G 15231, located 16 miles from the nearest Louisiana shoreline 2/8/2007 Apache Corporation, Structure Removal, SEA ES/SR 07-005 Eugene Island, Block 196, Lease OCS-G 00802, located 48 miles from the nearest Louisiana shoreline 2/12/2007 Chevron U.S.A., Inc., Structure Removal, SEA ES/SR 07-018 Ship Shoal, Block 100, Lease OCS-G 07750, located 22 miles from the nearest Louisiana shoreline 2/13/2007 Tana Exploration Company, LLC, Structure Removal, SEA ES/SR 07-023 Ship Shoal, Block 133, Lease OCS-G 23897, located 22 miles from the nearest Louisiana shoreline 2/13/2007 Maritech Resources, Inc., Structure Removal, SEA ES/SR 06-029 Grand Isle, Block 68, Lease OCS-G 15353, located 28 miles from the nearest Louisiana shoreline 2/16/2007 Energy Partners, LTD, Structure Removal, SEA ES/SR 07-025 South Timbalier, Block 41, Lease OCS-G 24954, located 13 miles from the nearest Louisiana shoreline 2/21/2007 CGGVERITAS, Geological & Geophysical Prospecting for Mineral Resources, SEA T07-02 Located in the central and western Gulf of Mexico south of Morgan City, Louisiana 2/22/2007 TGS-NOPEC Geophysical Company for Fugro-Geoteam AS, Geological & Geophysical Prospecting for Mineral Resources, SEA L07-04 Located in the central and western Gulf of Mexico south of Morgan City, Louisiana 2/22/2007 Energy Resources Technology, Inc., Structure Removal, SEA ES/SR 07-004 East Cameron, Block 231, Lease OCS-G 02038, located 69 miles from the nearest Louisiana shoreline 2/23/2007 Apache Corporation, Structure Removal, SEA ES/SR 06-076A Grand Isle, Block 82, Lease OCS-G 05659, located 29 miles from the nearest Louisiana shoreline 2/28/2007 Chevron U.S.A., Inc., Structure Removal, SEA ES/SR 07-027 Eugene Island, Block 113A, Lease OCS-G 04442, located 26 miles from the nearest Louisiana shoreline 3/7/2007 Maritech Resources, Inc., Structure Removal, SEA ES/SR 07-021 & 07-022 Eugene Island, Block 128, Lease OCS-00053, located 32 miles from the nearest Louisiana shoreline 3/7/2007 Chevron U.S.A., Inc., Structure Removal, SEA ES/SR 07-031 Mobile, Block 947, Lease OCS-G 07849, located 19 miles from the nearest Louisiana shoreline 3/7/2007 Walter Oil & Gas Corporation, Structure Removal, SEA ES/SR 07-026 Sabine Pass, Block 6, Lease OCS-G 18121, located 13 miles from the nearest Texas shoreline 3/7/2007 Chevron Environmental Management Company, Structure Removal, SEA ES/SR 07-028 Ship Shoal, Block 108, Lease OCS-00814, located 23 miles from the nearest Louisiana shoreline 3/7/2007 Newfield Exploration Company, Structure Removal, SEA ES/SR 07-032 West Delta, Block 102, Lease OCS-G 21130, located 23 miles from the nearest Louisiana Shoreline 3/7/2007 Newfield Exploration Company, Structure Removal, SEA ES/SR 07-030 Brazos, Block A7, Lease OCS-G 04558, located 25 miles from the nearest Texas 3/8/2007 Apache Corporation, Structure Removal, SEA ES/SR 06-119 High Island, Block A571, Lease OCS-G 02391, located 99 miles from the nearest Louisiana shoreline 3/8/2007 BP Exploration & Production Inc., Geological & Geophysical Prospecting for Mineral Resources for Schlumberger, SEA L07-07 Located in the central Gulf of Mexico south of Fourchon, Louisiana 3/8/2007 CGG Veritas, Geological & Geophysical Prospecting for Mineral Resources, SEA ES/SR L07-06 Located in the central Gulf of Mexico south of Fourchon, Louisiana 3/8/2007 Newfield Exploration Company, Structure Removal, SEA ES/SR 07-034 Ship Shoal, Block 57, Lease OCS-G 22696, located 15 miles from the nearest Louisiana shoreline 3/9/2007 Newfield Exploration Company, Structure Removal, SEA ES/SR 07-033 West Cameron, Block 146, Lease OCS-G 01996, located 22 miles from the nearest Louisiana shoreline 3/9/2007 Apache Corporation, Structure Removal, SEA ES/SR 06-120A Ship Shoal, Block 292, Lease OCS-G 12000, located 55 miles from the nearest Louisiana Shoreline 3/20/2007 Noble Energy, Inc., Structure Removal, SEA ES/SR 05-111, 05-112 & 05-113 Main Pass, Blocks 293, 305 & 306 and Leases OCS-G 21712, 01676 & 01677 respectively, located approximately 30 miles from the nearest Louisiana shoreline 3/26/2007 Noble Energy, Inc., Structure Removal, SEA ES/SR 05-164 Main Pass, Block 306, Lease OCS-G 01677, located 29 miles from the nearest Louisiana shoreline 3/26/2007 Walter Oil & Gas Corporation, Structure Removal, SEA ES/SR 07-020 Eugene Island, Block 72, Lease OCS-G 10720, located 18 miles from the nearest Louisiana shoreline 3/27/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 06-008A East Cameron, Block 231, Lease OCS-G 02038, located 69 miles from the nearest Louisiana shoreline 3/27/2007 Maritech Resources, Inc., Structure Removal, SEA ES/SR 06-027A South Marsh, Block 125, Lease OCS-G 02882, located 73 miles from the nearest Louisiana shoreline 3/27/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 07-003A East Cameron, Block 222, Lease OCS-G 02037, located 67 miles from the nearest Louisiana shoreline 3/28/2007 Energy Resource Technology, Inc., Structure Removal, SEA ES/SR 06-007A East Cameron, Block 231, Lease OCS-G 02038, located 65 miles from the nearest Louisiana shoreline 3/28/2007 Persons interested in reviewing environmental documents for the proposals listed above or obtaining information about SEAs and FONSIs prepared for activities on the Gulf of Mexico OCS are encouraged to contact MMS at the address or telephone listed in the FOR FURTHER INFORMATION section. Dated: April 12, 2007. Lars Herbst, Acting Regional Director, Gulf of Mexico OCS Region. [FR Doc. E7-9888 Filed 5-22-07; 8:45 am] BILLING CODE 4310-MR-P DEPARTMENT OF THE INTERIOR National Park Service Notice of Inventory Completion: Thomas Burke Memorial Washington State Museum, University of Washington, Seattle, WA AGENCY: National Park Service, Interior. ACTION: Notice. Notice is here given in accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), 25 U.S.C. 3003, of the completion of an inventory of human remains and funerary objects in the possession of the Thomas Burke Memorial Washington State Museum (Burke Museum), University of Washington, Seattle, WA. The human remains were removed from Benton, Franklin, Kittitas, Klickitat, and Yakima Counties, WA, and Wasco County, OR. This notice is published as part of the National Park Service's administrative responsibilities under NAGPRA, 25 U.S.C. 3003 (d)(3). The determinations in this notice are the sole responsibility of the museum, institution, or Federal agency that has control of the Native American human remains and associated funerary objects. The National Park Service is not responsible for the determinations in this notice. A detailed assessment of the human remains was made by Burke Museum professional staff in consultation with representatives of the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group. Prior to 1956, human remains representing a minimum of one individual were removed from the Columbia River above the Snake River (possibly Benton or Franklin County, WA) by R.C. Bunn, before the construction of the Priest Rapids Dam. The human remains were accessioned by the Burke Museum in 1971 (Burke Accn. #1971-17). No known individual was identified. The 97 associated funerary objects are 3 lots of beads (glass, shell, and bone), 6 stone pendants, 1 shell pendant, 1 fish vertebra, 2 pieces of red ochre, 1 metal ring, 1 copper button, 1 rolled copper tube bead, 9 fragments of copper ore, 5 seeds, 66 shell or shell fragments, and 1 unmodified stone. The context of the burial is unknown. The cultural items are consistent with cultural items typically found in context with burials in eastern Washington. The objects were found stored together with human remains and are consistent with other associated funerary objects. Therefore, the objects have been determined to be associated funerary objects. In 1964, human remains representing a minimum of one individual were removed from 45-BN-59 in Benton County, WA. The human remains were uncovered during a Washington State Highway Project and removed by a University of Washington Field Party led by Robert S. Kidd. The human remains were donated to the Burke Museum in 1966 (Burke Accn. #1966-76). No known individual was identified. No associated funerary objects are present. Early and late ethnographic documentation indicates that the present-day location of the Columbia River above the Snake River in Benton and Franklin Counties, WA is located within an overlapping aboriginal territory of the Cayuse, Palouse, Yakama, and Walla Walla (Daugherty 1973, Hale 1841, Mooney 1896, Ray 1936, Spier 1936, Sprague 1998, Stern 1998,) whose descendants are members of the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group. Information provided during consultation by the tribes listed above indicates that the aboriginal ancestors occupying this area were highly mobile and traveled the landscape for gathering resources as well as trade, and are all part of the more broadly defined Plateau cultural community. In 1953-1954, human remains representing a minimum of one individual were removed from 45-KT-21 in Kittitas County, WA, by the University of Washington during a field expedition led by Dr. Earl H. Swanson, Jr. The human remains were transferred from the University of Washington Department of Anthropology and accessioned by the Burke Museum in 1966 (Burke Accn. #1966-95). No known individual was identified. The 193 associated funerary objects are 38 cordage fragments, 1 mammal skin fragment, approximately 35 fish net fragments, 3 flakes, 4 mat fragments, 2 unmodified stones, 74 rush fragments, 6 fish bones, 2 rodent bones, 6 rabbit bones, 8 non-human mammal bones, 5 dentalium shells, and 9 pieces of cedar. Museum documentation indicates that the cultural items were found in connection with the human remains. The cultural items are consistent with cultural items typically found in context with burials in eastern Washington. Early and late published ethnographic documentation indicates that this was the aboriginal territory of the Moses-Columbia or Sinkiuse and Yakima (Daugherty 1973, Miller 1998, Mooney 1896, Ray 1936, Spier 1936) whose descendants are members of the Confederated Tribes and Bands of the Yakama Nation, Washington and Confederated Tribes of the Colville Reservation, Washington. Information provided during consultation by the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group indicates that the aboriginal ancestors occupying this area were highly mobile and traveled the landscape for gathering resources as well as trade, and are all part of the more broadly defined Plateau cultural community. Before 1916, human remains representing a minimum of one individual were removed from Memaloose Island in Klickitat County, WA. The human remains were donated by Lester L. Spessard to the Burke Museum in 1916 (Burke Accn. #1139). No known individual was identified. No associated funerary objects are present. Between 1960 and 1963, human remains representing a minimum of one individual were removed from the Bead Patch Site #2, Klickitat County, WA, by Dr. Harold Bergen. Dr. Bergen designated the site as Site #5 and referred to it as a possible cremation site. The human remains were donated by Dr. Bergen to the Burke Museum in 1989 (Burke Accn. #1989-57). No known individual was identified. No associated funerary objects are present. Between 1963 and 1967, human remains representing a minimum of three individuals were removed from the Juniper Site, also designated as Site #8, in Klickitat County, WA, by Dr. Bergen. Dr. Bergen donated the human remains to the Burke Museum in 1989 (Burke Accn. #1989-57). No known individuals were identified. The 507 funerary objects are 1 abrader; 2 adzes; 10 agate; 2 animal hide fragments; 2 antler wedges; 1 ground antler; 3 modified antler fragments; 1 bone awl; 2 metal axe blades; 3 bags of shell, shell beads, glass beads, red ochre, bone, plant material and rock; 4 lots of basketry fragments; 28 lots of beads; 14 bone fragments; 1 brass ornament; 1 brass handle; 1 brass knob; 6 brass bells; 22 buttons; 4 chains; 2 lots of charcoal; 12 chipped stone tools; 2 clay fragments; 2 copper ore clubs; 7 cones/tinklers; 1 coin; 2 stone cores; 2 digging sticks; 8 stone drills or drill fragments; 1 fish hook; 3 stone flakes; 2 glass fragments; 2 grooved abraders; 16 groundstone tools; 1 gun flint; 1 iron lid; 1 iron point; 5 stone knives; 3 leather fragments; 2 lead shots; 4 mauls; 20 metal fragments; 21 modified bone fragments; 1 mortar; 2 nail and fragments; 3 net weights; 1 obsidian tool; 1 pebble; 78 pendants; 6 pestles; 1 pipe bowl; 5 stone pipes; 74 points; 2 porcelain doll limbs; 8 lots of red ochre; 7 lots of metal rings; 1 salmon packing pestle; 5 seeds; 11 scrapers; 1 stone sculpture; 12 lots of shells including pendant, beads and fragments; 1 stone sinker; 2 unmodified stones; 13 modified stones including stone weight and tools; 1 lot of soil/dirt; 1 lot of spring fragments; 14 thimbles or thimble fragments; 1 tinkler/cone; 5 teeth fragments; 5 lots of tube beads; 9 utilized flakes; 6 lots of petrified wood; 1 copper cuff; and 1 gorget fragment. At an unknown date, human remains representing a minimum of one individual were removed from Rock Creek, Roosevelt, Klickitat County, WA. The human remains were found in the Burke collections in 1995 (Burke Accn. #1995-64). No known individual was identified. No associated funerary objects are present. In 1961, human remains representing a minimum of one individual were removed from Beek's Pasture near Sundale, designated as Site #39, Klickitat County, WA, by Dr. Bergen. The human remains were donated by Dr. Bergen to the Burke Museum in 1989 (Burke Accn. #1989-57). No known individual was identified. The 281 funerary objects are 4 abraders; 2 adze blades; 9 antler tool fragments; 1 bone awl; 13 lots of beads (bone, glass, shell, copper, some are strung); 3 bone tools; 16 bracelets or bracelet fragments; 10 copper buttons; 1 lot of charcoal; 4 chipped stone tools; 19 whale bone fragments; 2 iron club fragments; 5 copper fragments; 1 core; 2 fragments of an antler digging stick handle; 12 drills; 4 flakes; 8 grooved abraders; 7 stone knives; 1 maul; 4 fragments of modified bone; 2 modified shell fragments; 1 net gauge; 4 paint pots; 1 lot of pigment; 19 pendants or pendant fragments; 1 pestle; 8 pipes or pipe fragments; 1 bone point; 64 stone points; 1 iron point; 2 lots of red ochre; 4 scrapers; 7 lots of shell or shell fragments; 1 groundstone tool; 4 elk teeth; 3 utilized flakes; 4 burned wood fragments; 3 seeds; 5 metal fragments; 3 bone fragments; 1 antler fragments; 1 shell bead; 4 shell fragments; 2 fish vertebra; 3 unmodified stones; 3 charcoal fragments; and 1 copper gorget. Between 1957 and 1960, human remains representing a minimum of five individuals were removed from the Congdon Site (45-KL-41), designated as Site #3, Klickitat County, WA, by Dr. Bergen. The human remains were donated by Dr. Bergen to the Burke Museum in 1989 (Burke Accn. #1989-57). No known individuals were identified. The 174 funerary objects are 4 abraders, 1 adze blade, 1 antler tool, 2 apricot pit fragments, 7 atlatl weights, 14 lot of beads, 2 chert pieces, 1 bone awl, 2 unmodified mammal bones, 11 chipped stone tools, 4 clay fragments, 7 discoids, 3 drills, 1 flake, 1 graver, 7 groundstone tools, 1 maul, 3 modified bones, 1 mortar, 4 pendants, 77 stone points, 4 lots of red ochre, 2 unmodified stones, 5 stone scrapers, 5 shell fragments, 1 unmodified stone, 1 decorated stone, 1 utilized flake, and 1 antler wedge. Between 1950 and 1960, human remains representing a minimum of one individual were removed from Bead Patch #1, designated as Site #6, near the Dalles Dam in Klickitat County, WA, by Dr. Bergen. The human remains were donated to the Burke Museum in 1989 (Burke Accn. #1989-57). In 1996, the human remains were identified within a bag of ochre. No known individual was identified. The seven associated funerary objects are five fragments of unmodified quartz, one chipped stone tool, and one bag of ochre. In 1965, human remains representing a minimum of one individual were removed from 45-KL-6 in Klickitat County, WA, by a University of Washington Field Party led by Robert S. Kidd during a Washington State Highway Project. The human remains were accessioned by the Burke Museum in 1966 (Burke Accn. #1966-76). No known individual was identified. No associated funerary objects are present. In 1964, human remains representing a minimum of one individual were removed from 45-KL-2 in Klickitat County, WA, by a University of Washington Field Party led by Robert S. Kidd during a Washington State Highway Project. The human remains were donated to the Burke Museum in 1966 (Burke Accn. #1966-76). No known individual was identified. No associated funerary objects are present. Between 1956 and 1957, human remains representing a minimum of one individual were removed from the Sundale Site, designated as Site #17, near Rock Creek in Klickitat County, WA by Dr. Bergen. The human remains were donated by Dr. Bergen to the Burke Museum in 1989 (Burke Accn. #1989-57). The 7,349 funerary objects are 6,791 beads; 2 glass balls; 2 metal balls; 1 metal bell; 1 chert biface; 7 unmodified bird or mammal bones; 1 copper bracelet; 5 brass objects (unidentified); 3 bullet casings; 152 buttons;1 copper chain fragment; 7 chalk fragments; 1 wool cloth fragments; 1 copper ore fragment; 3 stone drills; 9 stone flakes; 30 metal fragments; 3 bone gaming pieces; 34 glass fragments; 2 metal hinges; 3 lots of leather fragments (1 with copper attached); 1 metal trunk lock or gorget; 5 marbles; 44 nails; 4 red ochre fragments; 2 copper ornaments; 17 pendants; 5 pestles; 2 pipes; 12 points; 5 copper or brass rings; 2 scrapers; 3 seed casings; 4 shell fragments; 1 snail shell; 8 modified stones; 91 unmodified stones; 1 string fragment; 1 clay tablet; 1 talon; 3 thimbles; 18 tinkling cones; 6 chipped stone tools; 38 animal teeth; 15 wood fragments; and 1 painted wood object. Between 1953 and 1954, human remains representing a minimum of one individual were removed from 45-KL-27 in Klickitat County, WA, as part of a University of Washington Field Project led by Warren Caldwell. The human remains were formally accessioned by the Burke Museum in 1966 (Burke Accn. #1966-86). No known individual was identified. The 17 associated funerary objects are 1 mammal bone fragment, 2 chipped stone tools, 1 chopper, 2 copper ore fragments, 1 net weight, 7 utilized flakes, 2 charcoal fragments, and 1 lot of red ochre. In 1953, human remains representing a minimum of 19 individuals were removed from Wakemap Mound (45-KL-26) in Klickitat County, WA, by a University of Washington Field Party led by Mr. Caldwell. The human remains were transferred by Mr. Caldwell to the Burke Museum and formally accessioned in 1966 (Burke Accn. #1966-86). No known individuals were identified. The 203 funerary objects are 1 abrader; 1 antler; 7 lots of beads; 9 lots of mammal, fish, whale and rodent bone; 2 bracelets; 1 buckle; 11 buttons; 40 ceramic/porcelain pieces; 1 ceramic cup; 3 lots of charcoal; 14 chipped stone tools; 7 choppers; 3 cloth fragments; 1 copper coin (Chinese); 1 copper bell; 2 lots of cordage; 1 core; 1 discoid; 1 glass doll; 1 drill; 1 lot of fiber matting; 1 metal file; 2 flakes; 24 glass fragments; 1 copper gorget; 5 lots of leather; 7 metal fragments; 1 nail; 1 needle; 1 net weight; 6 pendants; 1 porcelain pipe; 2 chert points; 12 projectile points; 4 scrapers; 2 screws; 1 lot of juniper seeds; 3 lots of shells; 1 leather shoe (in pieces); 1 lot of lead shot; 1 metal spring; 1 thimble; 1 unidentified twig; 5 utilized flakes; 2 lots of unmodified rock; and 8 lots of wood. Between 1940 and 1950, human remains representing a minimum of one individual were removed from an unknown area either in Klickitat County or Yakima County, WA, by Albert Mohr and Letitia Sample during expeditions throughout the Plateau Region of Washington. The collection was donated to the Burke Museum in 2001 by their son, Karl Mohr, and accessioned that same year (Burke Accn. #2001-136). In October 2003, the human remains were identified within the collection. No known individual was identified. The four associated funerary objects are stone fragments. The above mentioned sites border the Columbia River in Washington. Museum documentation indicates that the cultural items were found in connection with burials. The cultural items are consistent with cultural items typically found in context with burials in Washington. Early and late published ethnographic documentation indicates that this was the aboriginal territory of the Western Columbia River Sahaptins, Wasco, Wishram, Yakima, Walla Walla, Umatilla, Tenino, and Skin (Daugherty 1973, Hale 1841, Hunn and French 1998, Stern 1998, French and French 1998, Mooney 1896, Murdock 1938, Ray 1936 and 1974, Spier 1936) whose descendants are members of the Confederated Tribes and Bands of the Yakama Nation, Washington, Confederated Tribes of the Umatilla Reservation, Oregon; and Confederated Tribes of the Warm Springs Reservation of Oregon. Information provided by the representatives of the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group, during consultation indicates that the aboriginal ancestors occupying this area were highly mobile and traveled the landscape for gathering resources as well as trade, and are all part of the more broadly defined Plateau cultural community. The descendants of these Plateau communities of Eastern Washington and Eastern Oregon are now widely dispersed and are members of the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group. Officials of the Burke Museum have determined that, pursuant to 25 U.S.C. 3001 (9-10), the human remains described above represent the physical remains of 40 individuals of Native American ancestry. Officials of the Burke Museum also have determined that, pursuant to 25 U.S.C. 3001 (3)(A), the 8,832 objects described above are reasonably believed to have been placed with or near individual human remains at the time of death or later as part of the death rite or ceremony. Lastly, officials of the Burke Museum have determined that, pursuant to 25 U.S.C. 3001 (2), there is a relationship of shared group identity that can be reasonably traced between the Native American human remains and funerary objects and the Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Confederated Tribes and Bands of the Yakama Nation, Washington, for themselves and on behalf of the Wanapum Band, a non-federally recognized Indian group. The Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; Confederated Tribes and Bands of the Yakama Nation, Washington; and Wanapum Band, a non-federally recognized Indian group are claiming all the above mentioned human remains and funerary objects jointly. Representatives of any other Indian tribe that believes itself to be culturally affiliated with the human remains and funerary objects should contact Dr. Peter Lape, Burke Museum, University of Washington, Box 353010, Seattle, WA 98195-3010, telephone

(206)685-2282, before June 22, 2007. Repatriation of the human remains and funerary objects to the Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Confederated Tribes and Bands of the Yakama Nation, Washington, on behalf of themselves and the Wanapum Band, a non-federally recognized Indian group, may proceed after that date if no additional claimants come forward. The Burke Museum is responsible for notifying the Confederated Tribes and Bands of the Yakama Nation, Washington; Confederated Tribes of the Colville Reservation, Washington; Confederated Tribes of the Umatilla Reservation, Oregon; Confederated Tribes of the Warm Springs Reservation of Oregon; Nez Perce Tribe of Idaho; and Wanapum Band, a non-federally recognized Indian group that this notice has been published. Dated: May 14, 2007 Sherry Hutt, Manager, National NAGPRA Program. [FR Doc. E7-10012 Filed 5-22-07; 8:45 am] BILLING CODE 4312-50-S INTERNATIONAL TRADE COMMISSION [Investigation No. TA-2104-24] U.S.-Korea Free Trade Agreement: Potential Economy-Wde and Selected Sectoral Effects AGENCY: United States International Trade Commission. ACTION: Rescheduling of public hearing. SUMMARY: The Commission has rescheduled the public hearing in this investigation from June 7, 2007, to June 20, 2007. As announced in the notice of institution of the investigation published in the **Federal Register** on May 7, 2007 (72 FR 25779), the hearing will be held at the U.S. International Trade Commission building, 500 E Street, SW., Washington, DC; it will begin at 9:30 a.m. Certain dates relating to the filing of written statements and other documents have been changed; the revised schedule of dates is set out immediately below. All other requirements and procedures set out in the May 7, 2007, notice continue to apply. In the event that, as of the close of business on June 7, 2007, no witnesses are scheduled to appear at the hearing, the hearing will be canceled. Any person interested in attending the hearing as an observer or nonparticipant may call the Secretary to the Commission (202-205-2000) after June 7, 2007 for information concerning whether the hearing will be held. DATES: April 1, 2007: Receipt of request. June 6, 2007: Deadline for receipt of requests to appear at hearing. *June 6, 2007:* Deadline for filing pre-hearing briefs and statements. *June 20, 2007, 9:30 a.m.:* Public hearing. June 27, 2007: Deadline for filing post-hearing briefs and statements and all other written submissions. September 20, 2007: Anticipated date for transmitting report to USTR and the Congress. FOR FURTHER INFORMATION CONTACT: Project Leader Nannette Christ (202-205-3263; *nannette.christ@usitc.gov* ) or Deputy Project Leader Queena Fan (202-205-3055; *queena.fan@usitc.gov* ). For information on legal aspects, contact William Gearhart of the Office of the General Counsel (202-205-3091; *william.gearhart@usitc.gov* ). The media should contact Margaret O'Laughlin, Office of External Relations (202-205-1819; *margaret.olaughlin@usitc.gov* ). General information concerning the Commission may also be obtained by accessing its Internet address ( *http://www.usitc.gov* ). Hearing impaired individuals are advised that information on this matter can be obtained by contacting the TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Secretary at 202-205-2000. By order of the Commission. Issued: May 17, 2007. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E7-9871 Filed 5-22-07; 8:45 am] BILLING CODE 7020-02-P DEPARTMENT OF LABOR Employment and Training Administration Appointments to the Advisory Committee on Apprenticeship

(ACA)AGENCY: Employment and Training Administration, Labor. ACTION: Notice of ACA appointments. SUMMARY: The Employment and Training Administration hereby announces the appointment of 32 members to fill vacancies on the Advisory Committee on Apprenticeship (ACA), an advisory board to the Secretary. The ACA, which is authorized by Section 2 of the National Apprenticeship Act (29 U.S.C. 50), complies with the requirements of the Federal Advisory Committee Act (5 U.S.C., App.). The Committee will be an effective instrument for providing assistance, advice, and counsel to the Secretary of Labor and the Assistant Secretary for the Employment and Training Administration in the development and implementation of Administration policies and programs regarding apprenticeship. Members are appointed for one-year or two-year terms. The membership of the Committee shall include equal representation of employers, labor organizations, and the public. The National Association of State and Territorial Apprenticeship Directors (NASTAD) and the National Association of Government Labor Officials (NAGLO) will both be represented by their current President on the public group of the Committee. The Secretary shall appoint one of the public members as Chairperson of the Advisory Committee. FOR FURTHER INFORMATION CONTACT: Mr. Anthony Swoope, Administrator, Office of Apprenticeship, Employment and Training Administration, U.S. Department of Labor, Room N-5311, 200 Constitution Avenue, NW., Washington, DC 20210. Telephone:

(202)693-2796, (this is not a toll-free number). SUPPLEMENTARY INFORMATION: The following is a list of the Committee members by group: Represents: Employers Mr. Robert W. Baird, Vice President, Apprenticeship and Training, Standards and Safety, Independent Electrical Contractors, Inc., Alexandria, Virginia. Ms. Linda Bien, President and CEO, North East Medical Services, San Francisco, California. Ms. Phyllis Eisen, Vice President, Manufacturing Institute, Washington, DC. Ms. Julie A. Flik, Executive Vice President, Compass Group, North American Division, Bion Island, Mamaroneck, New York. Mr. Fred Haag, Senior Vice President—Electrical, Infrasource Inc., Madison, Mississippi. Mr. Kelvin D. Harrison, Technical Training Manager, Caterpillar, Inc., Peoria, Illinois. Mr. Neill J. Hopkins, Vice President of Skills Development, Computing Technology Industry Association, Oakbrook Terrace, Illinois. Mr. Frederick N. Humphreys, President & CEO, Home Builders Institute, Washington, DC. Mr. Stephen C. Mandes, Executive Director, National Institute for Metalworking Skills, Fairfax, Virginia. Ms. Karen T. Soehner, Corporate Compliance Officer, Family Senior Care, Saint Augustine, Florida. Mr. Robert Piper, Vice President of Workforce Development, Associated Builders and Contractors, Inc., Arlington, Virginia. Represents: Labor Mr. John T. Ahern, Business Manager, International Union of Operating Engineers Local 30, Richmond Hill, New York. Mr. George H. Bliss, III, Retired Director of Training Administration, United Association of Journeymen & Apprentices of the Plumbing & Pipe Fitting Industry of the U.S. & Canada, Washington, DC. Mr. Stephen A. Brown, Director, Construction Training Administration Department, International Union of Operating Engineers, Washington, DC. Mr. William P. Doyle, Attorney, Marine Engineers' Beneficial Association, Washington, DC. Dr. John S. Gaal, Director of Training Administration & Workforce Development, Carpenters' District Council of Greater St. Louis and Vicinity, St. Louis, Missouri. Mr. William K. Irwin, Jr., Executive Director, Carpenters International Training Fund, Las Vegas, Nevada. Mr. John Mason, Director, Seafarers International Union, Paul Hall Institute, Piney Point, Maryland. Mr. Joseph A. Miccio, Recording Secretary, Uniformed Firefighters Association of Greater New York, Local 94 I.A.F.F AFL-CIO, New York, New York. Mr. Edward Mullins, President, Sergeants Benevolent Association, New York, New York. Mr. Michael L. White, Executive Director of Apprenticeship and Training, International Union of Bridge, Structural, Ornamental and Reinforcing Iron Workers, Washington, DC. Represents: Public Dr. Philip J. Anderson, President, The National Association of Government Labor Officials, Frankfurt, Kentucky. Ms. Sharon C. Chu, Attorney, Law Offices of Sharon C. Chu, Rockville, Maryland. Mr. Guarione Diaz, President and Executive Director, Cuban American National Council, Inc., Miami, Florida. Ms. Rita DiMartino, New York, New York. Ms. Diana Enzi, Washington, DC. The Honorable Mufi Hannemann, Mayor of Honolulu, Honolulu, Hawaii. Mr. Thomas F. Hartnett—Chairperson, Attorney, Meyer, Suozzi, English and Klein, PC, Albany, New York. Ms. Jean Sickles, President, National Association of State and Territorial Apprenticeship Directors, Columbus, Ohio. Dr. Irving Pressley McPhail, President and CEO, The McPhail Group, Ltd, Ownings Mill, Maryland. Ms. Audrey Silverstein, Attorney, Merion, Pennsylvania. Mr. Charles Wilson, Department Head of Machine Tool Technology, Greenville Technical College, Greenwood, South Carolina. Nominees were selected from employer or national employer associations, religious, social welfare, academic, charitable organizations, community based organizations, national women's organizations, and state or local government. Signed at Washington, DC, this 17th day of May, 2007. Emily Stover DeRocco, Assistant Secretary for Employment and Training. [FR Doc. E7-9919 Filed 5-22-07; 8:45 am] BILLING CODE 4510-FR-P DEPARTMENT OF LABOR Employment and Training Administration Public Meeting of the Advisory Committee on Apprenticeship

(ACA)AGENCY: Employment and Training Administration, Labor. ACTION: Notice of an open ACA meeting. SUMMARY: Pursuant to section 10 of the Federal Advisory Committee Act (Pub. L. 92-463; 5 U.S.C. APP. 1), notice is hereby given of an open meeting of the Advisory Committee on Apprenticeship (ACA). *Time and Date:* The meeting will begin at approximately 8:30 a.m. on Tuesday, June 12, 2007, and continue until approximately 5 p.m. The meeting will reconvene at approximately 8:30 a.m. on Wednesday, June 13, 2007, and adjourn at approximately 5 p.m. *Place:* Holiday Inn on The Hill, 415 New Jersey Avenue, NW., Washington, DC 20001,

(202)638-1616. The agenda is subject to change due to time constraints and priority items which may come before the Committee between the time of this publication and the scheduled date of the ACA meeting. FOR FURTHER INFORMATION CONTACT: Mr. Anthony Swoope, Administrator, Office of Apprenticeship, U.S. Department of Labor, Room N-5311, 200 Constitution Avenue, NW., Washington, DC 20210. Telephone:

(202)693-2796, (this is not a toll-free number). Matters To Be Considered The agenda will focus on the following topics: • Status of the ACA's Recommendations to the Secretary • The 70th Anniversary of the National Apprenticeship Act • Workforce Innovations 2007 • Apprenticeship Integration with Workforce Investment Act

(WIA)System Status Members of the public are invited to attend the proceedings. Individuals with disabilities should contact Ms. Kenya Huckaby at

(202)693-3795 no later than Tuesday, June 5, 2007, if special accommodations are needed. Any member of the public who wishes to file written data or comments pertaining to the agenda may do so by sending the data or comments to Mr. Anthony Swoope, Administrator, Office of Apprenticeship, U.S. Department of Labor, Room N-5311, 200 Constitution Avenue, NW., Washington, DC 20210. Such submissions should be sent by Tuesday, June 5, 2007, to be included in the record for the meeting. Any member of the public who wishes to speak at the meeting should indicate the nature of the intended presentation and the amount of time needed by furnishing a written statement to the Designated Federal Official, Mr. Anthony Swoope, by Tuesday, June 5, 2007. The Chairperson will announce at the beginning of the meeting the extent to which time will permit the granting of such requests. Signed at Washington, DC, this 17th day of May, 2007. Emily Stover DeRocco, Assistant Secretary for Employment and Training. [FR Doc. E7-9920 Filed 5-22-07; 8:45 am] BILLING CODE 4510-FR-P LIBRARY OF CONGRESS Copyright Office [Docket No. 2007-1] Section 109 Report to Congress AGENCY: Copyright Office, Library of Congress. ACTION: Notice of Public Hearings. SUMMARY: The Copyright Office is holding public hearings on issues related to the operation of, and continued necessity for, the cable and satellite statutory licenses under the Copyright Act. DATES: Public hearings will be held from **July 23, 2007, through July 26, 2007** , in the Copyright Office Hearing Room, 4th Floor, James Madison Memorial Building, 101 Independence Avenue, S.E., Washington, D.C. 20540. Each daily session will begin at 10 a.m. Persons wishing to testify should notify the Copyright Office in writing no later than close of business on **June 15, 2007** . See SUPPLEMENTARY INFORMATION for additional filing requirements. ADDRESSES: Notices of intent to testify should be addressed to Ben Golant, Senior Attorney, and may be sent by mail or by e-mail to section109@loc.gov. The Copyright Office will notify each person expressing an intention to testify of the expected date and time of his/her testimony. See SUPPLEMENTARY INFORMATION for alternative means of submission and filing requirements. FOR FURTHER INFORMATION CONTACT: Ben Golant, Senior Attorney, and Tanya M. Sandros, Acting General Counsel, Copyright GC/I&R, P.O. Box 70400, Southwest Station, Washington, DC 20024. Telephone:

(202)707-8380. Telefax:

(202)707-8366. SUPPLEMENTARY INFORMATION: On December 8, 2004, the President signed the Satellite Home Viewer Extension and Reauthorization Act of 2004, a part of the Consolidated Appropriations Act of 2004. *See* Pub. L. No. 108-447, 118 Stat. 3394

(2004)(hereinafter “SHVERA”). Section 109 of the SHVERA requires the Copyright Office to examine and compare the statutory licensing systems for the cable and satellite television industries under Sections 111, 119, and 122 of the Copyright Act and recommend any necessary legislative changes no later that June 30, 2008. Under Section 109, Congress indicated that the report shall include, but not be limited to, the following:

(1)A comparison of the royalties paid by licensees under such sections, including historical rates of increases in these royalties, a comparison between the royalties under each such section and the prices paid in the marketplace for comparable programming;

(2)An analysis of the differences in the terms and conditions of the licenses under such sections, an analysis of whether these differences are required or justified by historical, technological, or regulatory differences that affect the satellite and cable industries, and an analysis of whether the cable or satellite industry is placed in a competitive disadvantage due to these terms and conditions;

(3)An analysis of whether the licenses under such sections are still justified by the bases upon which they were originally created;

(4)An analysis of the correlation, if any, between the royalties, or lack thereof, under such sections and the fees charged to cable and satellite subscribers, addressing whether cable and satellite companies have passed to subscribers any savings realized as a result of the royalty structure and amounts under such sections; and

(5)An analysis of issues that may arise with respect to the application of the licenses under such sections to the secondary transmissions of the primary transmissions of network stations and superstations that originate as digital signals, including issues that relate to the application of the unserved household limitations under Section 119 and to the determination of royalties of cable systems and satellite carriers. According to Section 109’s legislative history, the Copyright Office shall conduct a study of the Section 119 and Section 122 licenses for satellite, and the Section 111 license for cable, and to make recommendations for improvements to Congress no later than June 30, 2008. The legislative history further instructs that the Copyright Office must analyze the differences among the three licenses and consider whether they should be eliminated, changed, or maintained with the goal of harmonizing their operation. *See* H.R. Rep. No. 108-660, 108th Cong., 2d Sess., at 19 (2004). Earlier this year, we released a Notice of Inquiry seeking comment on several issues associated with the matters identified in Section 109 of the SHVERA. *See* 72 FR 19039 (April 16, 2007). To further supplement the record, the Office is announcing public hearings for the purpose of taking testimony from interested persons. This Notice describes the schedule and structure for the public hearings. *Public Hearings* . Because both the cable and satellite carrier statutory licenses have an impact on the operations and revenues of a number of industries, the Office believes that input from all affected industries is critical to a balanced and comprehensive report to Congress. Consequently, the Office has determined that a process involving both written comments and open hearings is essential to gathering the necessary information. We are, therefore, announcing the following schedule. The Office will conduct public hearings with interested parties in the Copyright Office Hearing Room at the Madison Building of the Library of Congress beginning on **July 23, 2007** , and running through **July 26, 2007** , if necessary. The format for these hearings will resemble the traditional Congressional hearing model in that there will be panels of witnesses that will present testimony to a panel of Copyright Office staff, headed by the Register of Copyrights. The Register and Office staff will ask questions of the various persons who testify, and interested parties may submit written questions to the Office by **July 2, 2007** , which may be addressed to specific witnesses, or the witnesses as a whole, at the discretion of the Office. The public hearings are open to the general public. However, in order to testify, interested persons must inform the Office of their intention to testify no later than the close of business on **June 15, 2007** . Notification of intention to testify must be in written form, either by letter or e-mail, and must be in the possession of the Copyright Office by the close of business on June 15th. Because of time constraints, and the need for the Copyright Office to schedule the panels of witnesses as soon as possible, it is recommended that persons wishing to testify deliver their notification by hand or by e-mail by the deadline. Notifications received after the **June 15th** deadline will not be accepted, and such person or persons will not be allowed to testify. The public hearings will begin at 10 a.m. each morning, and will continue until 5 p.m., unless otherwise directed by the Register of Copyrights. The Office will notify each witness who has filed a timely notice of intention to testify several days in advance of the date he/she is expected to appear and offer testimony. The Office will also notify each witness of the other witnesses who will appear on his/her panel. Because of space limitations in the Copyright Office Hearing Room, witnesses are encouraged to appear only on the date they are scheduled to offer testimony. Witnesses may bring with them on the day of their testimony a written summary of their oral testimony. Witnesses who bring such written summaries are asked to provide ten copies of the written summaries for use by the Office and others in attendance at the hearing. Transcription services of the public hearings will be provided by the Office. Those parties interested in obtaining transcripts of the hearings will need to purchase them from the transcription service. *Written Statements* . All persons who notify the Office of their intention to testify must submit a written statement of their testimony by the **July 2, 2007** , deadline. We are cognizant that formal written comments in response to the Office’s Section 109 NOI are also due on that date. Parties may submit these comments as their testimony, but an executive summary of such comments also must be submitted by the deadline. Because of time limitations, the Office encourages parties submitting written statements to deliver them to the Office by hand or by e-mail on or before the deadline. Facsimile transmissions of written statements will not be accepted. Parties submitting written statements are encouraged to include any and all information that they consider relevant to the statutory licensing of broadcast retransmissions. Parties may also include any exhibits that they deem relevant. Ten copies of each written statement must be submitted by the deadline. There is no prescribed format for the written statements. Parties are encouraged to organize their testimony in as clear and readable form as possible, and to provide a glossary of technical terms used in the written statement. Parties who do not wish to appear at the public hearings are nonetheless permitted, and encouraged, to submit written statements or summaries by the **July 2, 2007** deadline. *Reply Comments* . After the close of the public hearings, interested parties may submit comments in reply to the written statements and oral testimony. The reply phase is open to all parties, and is not limited to those who testified at the hearings and/or submitted written statements. Reply comments must be in the possession of the Copyright Office by **September 13, 2007** . We note that this is the date formal reply comments to the Section 109 NOI are due. Reply comments, then, should respond to the formal written comments submitted by parties, to the oral and written testimony submitted for the hearing, and to any other filings parties may wish to submit upon completion of the hearing. No facsimile transmissions of reply comments will be accepted. *Participation and Filing Requirements* . Each person wishing to testify must submit a formal written statement of his/her testimony no later than the close of business on **July 2, 2007** . Written statements will also be accepted from parties who do not wish to testify. Summaries of the formal written testimony, for purposes of oral testimony, may be submitted on the date of testimony. In addition, interested parties may submit written questions, for possible use by panel members of the Copyright Office during the course of hearings, no later than close of business on **July 2, 2007** . After the close of the hearings, interested parties may submit written reply comments to the testimony offered at the hearings, including any proposed legislative amendments, no later than close of business on **September 13, 2007** . If hand delivered by a private party, an original and five copies of any statements or comments should be brought to Library of Congress, U.S. Copyright Office, Office of General Counsel, 101 Independence Ave, 4th floor, Washington, D.C. 20559, between 8:30 a.m. and 5 p.m. The envelope should be addressed as follows: Ben Golant, Office of the General Counsel, U.S. Copyright Office. If delivered by a commercial courier, an original and five copies of a comment or reply comment must be delivered to the Congressional Courier Acceptance Site (“CCAS”) located at 2nd and D Streets, NE, Washington, D.C. between 8:30 a.m. and 4 p.m. The envelope should be addressed as follows: Office of the General Counsel, U.S. Copyright Office, LM 430, James Madison Building, 101 Independence Avenue, SE, Washington, DC. Please note that CCAS will not accept delivery by means of overnight delivery services such as Federal Express, United Parcel Service or DHL. If sent by mail (including overnight delivery using U.S. Postal Service Express Mail), an original and five copies of a comment or reply comment should be addressed to U.S. Copyright Office, Copyright GC/I&R, P.O. Box 70400, Southwest Station, Washington, DC 20024. If sent by e-mail, please send to section109@loc.gov. *Scope of the Proceeding* . In accordance with the text of Section 109 of the SHVERA, the Copyright Office will be conducting a global review of the cable and satellite carrier statutory licenses. The hearing will focus on issues related to the retransmission of over-the-air broadcast signals. Any matters raised in the Section 109 NOI are subject to discussion and debate. Conclusion We hereby provide notice to the public on the scheduling of hearings associated with Section 109 of the SHVERA and the retention, reform, or elimination of Sections 111, 119, and 122 of the Copyright Act. Dated: May 14, 2007 Marybeth Peters, Register of Copyrights, U.S. Copyright Office. [FR Doc. E7-9836 Filed 5-22-06; 8:45 am] BILLING CODE 1410-30-S NATIONAL INSTITUTE FOR LITERACY National Institute for Literacy Advisory Board; Meeting AGENCY: National Institute for Literacy. ACTION: Notice of an open meeting with a closed session. SUMMARY: This notice sets forth the schedule and proposed agenda of an upcoming open meeting of the National Institute for Literacy Advisory Board. The notice also describes the functions of the Committee. Notice of this meeting is required by section 10(a)(2) of the Federal Advisory Committee Act and is intended to notify the public of its opportunity to attend. DATES: June 13-14, 2007. TIME: June 13 from 8:30 a.m.-4:30 p.m.; June 14 from 8:30 a.m.-2 p.m.; closed session June 13 from 4:30 p.m.-5:30 p.m. ADDRESSES: 1775 I St., NW., Suite 730, Washington, DC 20006. FOR FURTHER INFORMATION CONTACT: Steve Langley, Staff Assistant, the National Institute for Literacy; 1775 I St., NW., Suite 730; phone:

(202)233-2043; fax:

(202)233-2050; e-mail: *slangley@nifl.gov.* Individuals who use a telecommunications device for the deaf

(TDD)may call the Federal Information Relay Service

(FRS)at 1-800-877-8339. SUPPLEMENTARY INFORMATION: The National Institute for Literacy Advisory Board is authorized by section 242 of the Workforce Investment Act of 1998, Pub. L. 105-220 (20 U.S.C. 9252). The Board consists of 10 individuals appointed by the President with the advice and consent of the Senate. The Board advises and makes recommendations to the Interagency Group that administers the Institute. The Interagency Group is composed of the Secretaries of Education, Labor, and Health and Human Services. The Interagency Group considers the Board's recommendations in planning the goals of the Institute and in implementing any programs to achieve those goals. Specifically, the Board performs the following functions:

(a)Makes recommendations concerning the appointment of the Director and the staff of the Institute;

(b)provides independent advice on operation of the Institute; and

(c)receives reports from the Interagency Group and the Institute's Director. The purpose of this meeting is to discuss the Institute's future and current program priorities; status of on-going Institute work; other relevant literacy activities and issues; and other Board business as necessary. On June 13, 2007 from 4:30 p.m. to 5:30 p.m., the Board will meet in closed session in order to discuss personnel issues. This discussion relates to the internal personnel rules and practices of the Institute, including consideration of the Director's performance and salary. The discussion is likely to disclose information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personnel privacy. The discussion must therefore be held in closed session under exemptions 2 and 6 of the Government in the Sunshine Act, 5 U.S.C. 552b

(2)and (6). A summary of the activities at the closed session and related matters that are informative to the public and consistent with the policy of 5 U.S.C. 552b will be available to the public within 14 days of the meeting. Individuals who will need accommodations for a disability in order to attend the meeting ( *e.g.* , interpreting services, assistance listening devices, or materials in alternative format) should notify Steve Langley at 202-233-2043 no later than June 4, 2007. We will attempt to meet requests for accommodations after this date but cannot guarantee their availability. The meeting site is accessible to individuals with disabilities. *Request for Public Written Comments* . The public may send written comments to the Advisory Board no later than 5 p.m. on June 4, 2007, to Steve Langley at the National Institute for Literacy, 1775 I St., NW., Suite 730, Washington, DC 20006, e-mail: *slangley@nifl.gov* . Records are kept of all Committee proceedings and are available for public inspection at the National Institute for Literacy, 1775 I St., NW., Suite 730, Washington, DC 20006, from the hours of 9 a.m. to 5 p.m., Eastern Standard Time Monday through Friday. *Electronic Access to This Document:* You may view this document, as well as all other documents of this Department published in the **Federal Register** , in text or Adobe Portable Document Format

(PDF)on the Internet at the following site: *www.ed.gov/news/fedregister/index.html* . To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free at 1-888-293-6498; or in the Washington, DC, area at

(202)512-1530. Note: The official version of this document is the document published in the **Federal Register** . Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: *www.gpoaccess.gov/nara/index.html.* Sandra Baxter, Director, The National Institute for Literacy. [FR Doc. E7-9859 Filed 5-22-07; 8:45 am] BILLING CODE 6055-01-P NATIONAL SCIENCE FOUNDATION Notice of Intent to Seek Approval to Renew an Information Collection AGENCY: National Science Foundation. ACTION: Notice and request for comments. SUMMARY: The National Science Foundation

(NSF)is announcing plans to request clearance of this collection. In accordance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 (Pub. L. 104-13), we are providing opportunity for public comment on this action. After obtaining and considering public comment, NSF will prepare the submission requesting that OMB approve clearance of this collection for no longer than 3 years. DATES: Written comments on this notice must be received by July 23, 2007 to be assured of consideration. Comments received after that date will be considered to the extent practicable. FOR ADDITIONAL INFORMATION OR COMMENTS: Contact Suzanne H. Plimpton, Reports Clearance Officer, National Science Foundation, 4201 Wilson Boulevard, Suite 295, Arlington, Virginia 22230; telephone

(703)292-7556; or send e-mail to *splimpto@nsf.gov.* You also may obtain a copy of the data collection instrument and instructions from Ms. Plimpton. SUPPLEMENTARY INFORMATION: *Title of Collection:* Medical Clearance Process for Deployment to Antarctica. *OMB Number:* 3145-0177. *Expiration Date of Approval:* September 30, 2007. *Type of Request: * Intent to seek approval to renew an information collection for three years. Abstract A. Proposed Project All individuals who anticipate deploying to Antarctica and to certain regions of the Arctic under the auspices of the United States Antarctic Program are required to take and pass a rigorous physical examination prior to deploying. The physical examination includes a medical history, medical examination, a dental examination and for those persons planning to winter over in Antarctica a psychological examination is also required. The requirement for this determination of physical status is found in 42 U.S.C. 1870 (Authority) and 62 FR 31522, June 10, 1997 (Source), unless otherwise noted. This part sets forth the procedures for medical screening to determine whether candidates for participation in the United States Antarctic [[Page 216]] Program

(USAP)are physically qualified and psychologically adapted for assignment or travel to Antarctica. Medical screening examinations are necessary to determine the presence of any physical or psychological conditions that would threaten the health or safety of the candidate or other USAP participants or that could not be effectively treated by the limited medical care capabilities in Antarctica.

(b)Presidential Memorandum No. 6646 (February 5, 1982) (available from the National Science Foundation, Office of Polar Programs, Room 755, 4201 Wilson Blvd., Arlington, VA 22230) sets forth the National Science Foundation's overall management responsibilities for the entire United States national program in Antarctica. B. Use of the Information 1. *Form NSF-1422/1462/1452* , National Science Foundation—Polar Physical Examination (Antarctica/Arctic/Official Visitors) Medical History, will be used by the individual to record the individual's family and personal medical histories. It is a five-page form that includes the individual's and the individual's emergency point-of-contact's name, address, and telephone numbers. It contains the individual's email address, employment affiliation and dates and locations of current and previous polar deployments. It also includes a signed certification of the accuracy of the information and understandings of refusal to provide the information or providing false information. The agency's contractors' reviewing physicians and medical staff complete the sections of the form that indicate when the documents were received and whether or not the person qualified for polar deployment, in which season the person is qualified to deploy and where disqualified the reasons. 2. *Form NSF-1423/1463/1453* , Polar Physical Examination—Antarctica/Arctic/Official Visitors, will be used by the individual's physician to document specific medical examination results and the overall status of the individual's health. It is a two-page form which also provides for the signatures of both the patient and the examining physician, as well as contact information about the examining physician. Finally, it contains the name, address and telephone number of the agency's contractor that collects and retains the information. 3. *Form NSF-1426/1466/1456* , National Science Foundation—Polar Physical Examination (Antarctica/Arctic/Official Visitors) Medical History Interval Screening, will only be used by individuals who are under the age of 40 and who successfully took and passed a polar examination the previous season or not more than 24 months prior to current deployment date. It allows the otherwise healthy individual to update his or her medical data without having to take a physical examination every year as opposed to those over 40 years of age who must be examined annually. 4. *Form NSF-1465/14525/1455* , Polar Dental Examination- Antarctica/Arctic/Official Visitors, will be used by the examining dentist to document the status of the individual's teeth and to document when the individual was examined. It will also be used by the contractor's reviewing dentist to document whether or not the individual is dentally cleared to deploy to the polar regions. 5. *Form NSF 1428/1468 Medical Waivers—Antarctic/Arctic:* Any individual who is determined to be not physically qualified for polar deployment may request an administrative waiver of the medical screening criteria. This information includes signing a Request for Waiver that is notarized or otherwise legally acceptable in accordance with penalty of perjury statutes, and obtaining an Employer Statement of Support. Individuals on a case-by-case basis may also be required to submit additional medical documentation and a letter from the individual's physician(s) regarding the individual's medical suitability for Antarctic deployment. 6. *Other information requested:* In addition to the numbered forms and other information mentioned above, the USAP medical screening package includes the following: —The Medical Risks for NSF-Sponsored Personnel Traveling to Antarctica —The NSF Privacy Notice —The NSF Medical Screening for Blood-borne Pathogens/Consent for HIV Testing —The NSF Authorization for Treatment of Field-Team Member/Participant Under the Age of 18 Years. This should only be sent to the individuals who are under 18 years of age. —The Dear Doctor and Dear Dentist letters, which provide specific laboratory and x-ray requirements, as well as other instructions. 7. *There are two other, non-medical forms included in the mailing:* —The Personal Information Form—NSF Form Number 1458 includes a Privacy Act notice. This form is used to collect information on current address and contact numbers, date and place of birth, nationality, citizenship, emergency point of contact information, travel dates, clothing sizes so that we may properly outfit those individuals who deploy, work-site information and prior deployment history. —The Participant Notification—Important Notice for Participants—NSF Form 1457 in the United States Antarctic Program. This form provides information on the laws of the nations through which program participants must transit in route to Antarctica, regarding the transport, possession and use of illegal substances and the possibility of criminal prosecution of caught, tried and convicted. *Estimate of Burden:* Public reporting burden for this collection of information varies according to the overall health of the individual, the amount of time it takes to access the forms online and print them, the amount of research required to complete the forms, the time it takes to make an appointment, take the examination and schedule and complete any follow-up medical, dental or psychological requirements and the completeness of the forms submitted. The estimated time is up to six weeks from the time the individual receives the forms until he or she is notified by the contractor of their final clearance status. An additional period of up to eight weeks may be required for the individual who was disqualified to be notified of the disqualification, to request and receive the waiver packet, to obtain employer support and complete the waiver request, to do any follow-up testing, to return the waiver request to the contractor plus any follow-up information, for the contractor to get the completed packet to the National Science Foundation, and for the NSF to make and promulgate a decision. *Respondents:* All individuals deploying to the Antarctic under the auspices of the United States Antarctic Program and certain Arctic areas must complete these forms. There are approximately 3,000 submissions per year, with a small percentage (c. 3%) under the age of 40 who provide annual submissions but with less information. *Estimated Number of Responses per Form:* Responses range from 2 to approximately 238 responses. *Estimated Total Annual Burden on Respondents:* 28,728 hours. *Frequency of Responses:* Individuals must complete the forms annually to be current within 12 months of their anticipated deployment dates. Depending on individual medical status some persons may require additional laboratory results to be current within two to six-weeks of anticipated deployment. *Comments:* Comments are invited on

(a)Whether the proposed collection of information is necessary for the proper performance of the functions of the Agency, including whether the information shall have practical utility;

(b)the accuracy of the Agency's estimate of the burden of the proposed collection of information;

(c)ways to enhance the quality, utility, and clarity of the information on respondents, including through the use of automated collection techniques or other forms of information technology; and

(d)ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Dated: May 16, 2007. Suzanne H. Plimpton, Reports Clearance Officer, National Science Foundation. [FR Doc. 07-2549 Filed 5-22-07; 8:45 am]

Connectionstraces to 16

Traces to 16 documents

U.S. Code